var title_f1_62_2016="Ventilator delivery B agonist";
var content_f1_62_2016=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchodilator administration via mechanical ventilator",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Continuous beta agonist nebulization set-up for ventilator delivery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Murphy, S. Presented at American Academy of Allergy and Immunology 1991. With permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_62_2016=[""].join("\n");
var outline_f1_62_2016=null;
var title_f1_62_2017="ICE transseptal";
var content_f1_62_2017=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    This ultrasound image is an intracardiac echocardiographic illustration of a transseptal catheterization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 411px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ICE catheter is in the right atrium and shows the needle tenting the interatrial septum before the puncture occurs providing access to the left atrium. Transseptal catheterization is a necessary first step to PMBV.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_62_2017=[""].join("\n");
var outline_f1_62_2017=null;
var title_f1_62_2018="Obstructed common hepatic duct from impacted cystic duct stone";
var content_f1_62_2018=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Obstruction of the common hepatic duct caused by impacted cystic duct stone (Mirizzi syndrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 428px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mirizzi syndrome. Impaction of a large gallstone in the cystic duct, with extrinsic obstruction of the adjacent common hepatic duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Blackbourne LH. Advanced Surgical Recall, 2nd ed, Lippincott Williams &amp; Wilkins, Baltimore 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_62_2018=[""].join("\n");
var outline_f1_62_2018=null;
var title_f1_62_2019="Distal tibia intraosseous site";
var content_f1_62_2019=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Distal tibial intraosseous access site",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 344px; height: 536px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Entry site at the distal tibia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hodge Dee III. Intraosseous infusion. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_62_2019=[""].join("\n");
var outline_f1_62_2019=null;
var title_f1_62_2020="Topical thrombin: Pediatric drug information";
var content_f1_62_2020=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Topical thrombin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?39/42/40612?source=see_link\">",
"    see \"Topical thrombin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/50/14115?source=see_link\">",
"    see \"Topical thrombin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F227307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Evithrom&reg;;",
"     </li>",
"     <li>",
"      Recothrom&reg;;",
"     </li>",
"     <li>",
"      Thrombi-Gel&reg;;",
"     </li>",
"     <li>",
"      Thrombi-Pad&reg;;",
"     </li>",
"     <li>",
"      Thrombin-JMI&reg;;",
"     </li>",
"     <li>",
"      Thrombin-JMI&reg; Epistaxis Kit;",
"     </li>",
"     <li>",
"      Thrombin-JMI&reg; Pump Spray Kit;",
"     </li>",
"     <li>",
"      Thrombin-JMI&reg; Syringe Spray Kit",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1062588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Hemostatic Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1062584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/42/40612?source=see_link\">",
"      see \"Topical thrombin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Hemostasis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder or solution formulations:  Apply 1000-2000 units/mL solution directly or via absorbable gelatin sponge to the site of bleeding or oozing surface; Thrombin-JMI&reg; may also be applied in dry powder form directly to the site. For general use in plastic surgery, dental extractions, skin grafting, etc, solutions containing approximately 100 units/mL are frequently used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombi-Gel&reg;10, 40, 100: Adults: Wet product with up to 3 mL, 10 mL, or 20 mL, respectively, of 0.9% sodium chloride or SWI; apply directly over source of the bleeding with manual pressure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombi-Pad&reg;: Adults: Apply pad directly over source of bleeding. May apply dry or wetted with up to 10 mL of 0.9% sodium chloride. If desired, product may be left in place for up to 24 hours; do not leave in the body",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F227299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pad, topical [preservative free; bovine derived]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Thrombi-Pad&reg; 3x3: &ge;200 units (10s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder for reconstitution, topical [bovine derived]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thrombin-JMI&reg;: 5000 units, 20,000 units [supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thrombin-JMI&reg; Epistaxis kit: 5000 units [supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thrombin-JMI&reg; Pump Spray Kit: 20,000 units [supplied with diluents]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thrombin-JMI&reg; Syringe Spray Kit: 5000 units; 20,000 units [supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for reconstitution, topical [preservative free; recombinant]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Recothrom&reg;: 5000 units; 20,000 units [production involves products derived from hamster and snake sources; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical [human derived]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Evithrom&reg;: 800-1200 units/mL (2 mL, 5 mL, 20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sponge, topical [preservative free; bovine derived]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thrombi-Gel&reg; 10: &ge;1000 units (10s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thrombi-Gel&reg; 40: &ge;1000 units (5s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thrombi-Gel&reg; 100: &ge;2000 units (5s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F227286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1062591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Not for injection",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Powder or solution formulations: May be applied directly as a powder (Thrombin-JMI&reg;) or as reconstituted solution; the most effective hemostasis results when the thrombin mixes freely with blood as it appears; use NS to reconstitute powder to 1000-2000 units/mL concentration; (Evithrom&reg; must be thawed prior to use and requires no further dilution). The recipient surface should be sponged (not wiped) free of blood before application; do not sponge",
"     <b>",
"      treated",
"     </b>",
"     surfaces to assure that clot remains securely in place. Refer to manufacturer&rsquo;s information for more specific application information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pad or sponge formulations: May cut or roll Thrombi-Gel&reg; to desired shape prior to wetting; once wetted and prior to applying, knead thoroughly to saturate the pad remove trapped air bubbles. Thrombi-Pad&reg; may be applied dry or wet.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1062586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Evithrom&reg;: Store frozen vials at -18&deg;C for up to 2 years; unopened vials may be stored at 2&deg;C to 8&deg;C for up to 30 days; stable at room temperature for 24 hours; do not refreeze after thawing; do not refrigerate once at room temperature.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recothrom&reg;: Store at room temperature; reconstituted solutions may be stored refrigerated for 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombi-Gel&reg;: Store at 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F). After wetting with SWI or 0.9% sodium chloride, use within 3 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombi-Pad&reg;: Store at 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F). If pad is wetted with 0.9% sodium chloride, use within 1 hour.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombin-JMI&reg;: Store vials at room temperature; reconstituted vials may be stored in refrigerator for 24 hours or at room temperature for 8 hours.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1062590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemostasis whenever minor bleeding from capillaries and small venules is accessible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombi-Gel&reg;; Thrombi-Pad&reg;: Temporary control as trauma dressing for moderate-to-severe bleeding wounds; control of surface bleeding from vascular access sites and percutaneous catheter/ tubes",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5663226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       For topical use only. Do not administer intravenously or intra-arterially.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       To reduce the risk of intravascular administration, the Institute for Safe Medication Practices (ISMP) has the following recommendations:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;\">",
"       - Prepare, label, and dispense topical thrombin from the pharmacy department (including doses used in the operating room).",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;\">",
"       - Do not leave vial or syringe at bedside.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;\">",
"       - Add auxiliary label to all labels and syringes stating &ldquo;For topical use only - do not inject&rdquo;.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;\">",
"       - When appropriate, use solutions which can be applied with an absorbable gelatin sponge or use a dry form on oozing surfaces.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;\">",
"       - When appropriate, use spray kits to help differentiate between parenteral products.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F227316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Bleeding, aPTT increased, INR increased, lymphocyte count decreased, neutrophil count increased, PT prolonged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Incision site complication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Antibody development, hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1062593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to thrombin or any component; not to be injected directly into circulatory system; Evithrom&reg; is contraindicated for the treatment of massive or brisk arterial bleeding and in patients with a known anaphylactic or severe systemic reaction to blood products; Recothrom&reg; is contraindicated for the treatment of severe or brisk arterial bleeding and in patients with hypersensitivity to hamster or snake proteins; Thrombin-JMI&reg; and Thrombi-Pad&reg; are contraindicated in patients with hypersensitivity to material of bovine origin; Thrombi-Gel&reg; should not be used in closure of skin incisions due to possible interference with healing of skin edges",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1062583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      For topical use only - do not inject",
"     </b>",
"     ; injection may result in extensive intravascular clotting and death. Use of bovine-source topical thrombin has been associated with abnormalities in hemostasis ranging from asymptomatic alterations in PT and PTT to severe bleeding or thrombosis which have rarely been fatal",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . These hemostatic effects may be related to formation of antibodies against bovine thrombin and/or factor V which in some cases may cross react with human factor V resulting in factor V deficiency; patients with antibodies to bovine thrombin should not receive topical thrombin again. Thrombi-Gel&reg;, Thrombi-Pad&reg; should not be used in the presence of infection; use caution in areas of contamination. Thrombi-Pad&reg; is nonabsorbable and should not be left in the body.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F227294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F227296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5663227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adequate reproduction studies have not been conducted. Reproduction studies conducted with the solvent/detergent used in processing the human-derived product showed adverse events in animals. Only residual levels of the solvent/detergent would be expected to remain in the finished product.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1062582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Activates platelets and catalyzes the conversion of fibrinogen to fibrin",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1062594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     One unit is amount required to clot 1 mL of standardized fibrinogen solution in 15 seconds",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12840 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-AB4CE9AEE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_62_2020=[""].join("\n");
var outline_f1_62_2020=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708964\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227307\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062588\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062584\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227299\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227286\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062591\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062586\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062590\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5663226\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227316\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062593\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062583\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300134\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227294\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227296\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5663227\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062582\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062594\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12840\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12840|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/42/40612?source=related_link\">",
"      Topical thrombin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/50/14115?source=related_link\">",
"      Topical thrombin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_62_2021="Treatment of hypertension in asthma and COPD";
var content_f1_62_2021=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of hypertension in asthma and COPD",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/62/2021/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/62/2021/contributors\">",
"     Steven E Weinberger, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/62/2021/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/62/2021/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/62/2021/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/62/2021/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/62/2021/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/62/2021/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/62/2021/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/62/2021/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of hypertension in a patient with asthma or chronic obstructive pulmonary disease (COPD) is a common problem owing to the high prevalence of each condition in the adult population. It may be made difficult by the asthma-exacerbating effect of some antihypertensives. As an example, beta blockers should be used with great caution or not at all in patients with chronic asthma (but not chronic obstructive pulmonary disease) or acute allergic or exercise-induced bronchospasm. The angiotensin converting enzyme (ACE) inhibitors, among the most widely used antihypertensive drugs, can induce a bothersome cough that, although not damaging to the lungs, often can be confused with cough due to such underlying pulmonary diseases such as asthma and COPD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BETA BLOCKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with asthma, beta blockers can cause increased bronchial obstruction and airway reactivity, and resistance to the effects of inhaled or oral beta receptor agonists (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"     terbutaline",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2021/abstract/1\">",
"     1",
"    </a>",
"    ]. Even topical ophthalmic administration of nonselective beta blockers for the treatment of glaucoma has led to asthmatic exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2021/abstract/2\">",
"     2",
"    </a>",
"    ]. However, beta-blockers appear to be safe in patients with COPD and indeed may reduce mortality and exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2021/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical effects of more &szlig;1-selective beta blockers on pulmonary function appear to be less severe. A meta-analysis drawn from randomized, blinded, placebo-controlled trials identified approximately 400 patients with either asthma or COPD and reversible bronchoconstriction, as evidenced by a greater than 15 percent improvement in FEV1 following bronchodilator treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2021/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Studies of both single-dose and long-term use were included, and the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Single-dose use was associated with an 8 percent decrease in FEV1, but a 5 to 9 percent increase in bronchodilator response.",
"     </li>",
"     <li>",
"      Sustained use was not associated with a significant change in baseline FEV1.",
"     </li>",
"     <li>",
"      Long-term therapy did not increase respiratory symptoms or the use of inhaled beta agonists.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This meta-analysis focused only on patients with mild or moderate reversible airway disease. Therefore, even &szlig;1-selective agents should be used with caution in patients with severe obstruction or markedly reduced baseline pulmonary function.",
"   </p>",
"   <p>",
"    The precise mechanism of beta blocker-induced bronchoconstriction is unknown. Parasympathetic pathways of airway control may be involved, since the anticholinergic drug oxitropium bromide can inhibit the effect of inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2021/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ACE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common side effect of therapy with ACE inhibitors is cough, which develops in three to 20 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2021/abstract/7\">",
"     7",
"    </a>",
"    ]. The cough is typically described as dry, irritative, and persistent, but rarely productive. The possibility that this cough may represent an asthma equivalent has been suggested by the demonstration of bronchial hyperresponsiveness in some affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2021/abstract/8\">",
"     8",
"    </a>",
"    ], but this has not been a consistent finding [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2021/abstract/9\">",
"     9",
"    </a>",
"    ]. There are also conflicting data on whether patients with underlying asthma are more likely than nonasthmatics to develop cough after ACE inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2021/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link&amp;anchor=H6#H6\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\", section on 'Cough'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study of adverse respiratory reactions to ACE inhibitors found that reactions diagnosed as asthma, bronchospasm, or dyspnea were reported with one-tenth the frequency of cough [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2021/abstract/11\">",
"     11",
"    </a>",
"    ]. Although exacerbation of airflow obstruction has not been a significant problem in asthmatic patients, several cases of worsening asthma have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2021/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At present, ACE inhibitors are currently not first-line therapy in patients with asthma or COPD. However, these agents are",
"    <strong>",
"     not",
"    </strong>",
"    contraindicated in these disorders as long as the clinician is aware of the relatively uncommon complication of worsening airflow obstruction. An alternative, when it is desirable to block the renin-angiotensin system, is administration of an angiotensin II receptor blocker.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANGIOTENSIN RECEPTOR BLOCKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin II receptor blockers do not appear to induce cough. Furthermore, among patients with symptomatic asthma, one study found no increase in cough or bronchial hyperreactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2021/abstract/12\">",
"     12",
"    </a>",
"    ]. The authors concluded that these drugs may have a safety profile in asthmatics similar to calcium channel blockers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25224?source=see_link\">",
"     \"Renin-angiotensin system inhibition in the treatment of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIURETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diuretics can be effectively used in asthmatics, but the potential for serious hypokalemia must be recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2021/abstract/13\">",
"     13",
"    </a>",
"    ]. This problem is related to the ability of inhaled &szlig;2-receptor agonists to drive potassium into the cells (acutely lowering the plasma potassium concentration by as much as 0.5 to 1",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    and of oral corticosteroids to mildly enhance urinary potassium excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2021/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=see_link&amp;anchor=H17666854#H17666854\">",
"     \"Causes of hypokalemia\", section on 'Elevated beta-adrenergic activity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a second potential problem with diuretic therapy in patients with COPD and chronic hypercapnia. In this setting, diuretic-induced metabolic alkalosis can suppress the ventilatory drive, potentially exacerbating the degree of hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2021/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, it is safest to administer only low thiazide doses (12.5 to 25 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    ) to nonedematous hypertensive patients with asthma or COPD. Low-dose therapy may be both effective and less likely to produce unwanted side effects such as hypokalemia and metabolic alkalosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15350?source=see_link\">",
"     \"Use of thiazide diuretics in patients with primary hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CALCIUM CHANNEL BLOCKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The calcium channel blockers (especially those of the dihydropyridine group, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"     nicardipine",
"    </a>",
"    ) are excellent agents for the treatment of hypertension in asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2021/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition to effectively lowering the blood pressure, they also have the theoretical advantages of opposing muscle contraction in tracheobronchial smooth muscle, inhibiting mast cell degranulation, and possibly reinforcing the bronchodilator effect of beta agonists. Nifedipine, for example, can antagonize the bronchoconstricting effects of antigen, histamine, or cold air challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2021/abstract/17\">",
"     17",
"    </a>",
"    ], although most studies have shown no significant clinical benefit of calcium antagonists in asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2021/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When examined in clinical trials, these agents have been shown to modestly improve or not affect pulmonary function in asthmatics [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2021/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. Thus, the use of a low-dose thiazide alone or with a calcium channel blocker represents the preferred regimen for the initial management of the hypertensive asthmatic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32966?source=see_link\">",
"     \"Major side effects and safety of calcium channel blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SYMPATHETIC BLOCKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     Clonidine",
"    </a>",
"    and other alpha-2-receptor agonists (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    , guanabenz) should be used with caution in asthmatics. Oral doses of these agents do not change baseline air flow in asthmatics, but they do increase bronchial reactivity to inhaled histamine [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2021/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     OTHER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little specific information is available for the remaining antihypertensive agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    . However, if asthma occurs with these or other drugs, one should always consider the possibility that the tartrazine dye within the drug preparation may be the culprit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13075016\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of hypertension in a patient with asthma or chronic obstructive pulmonary disease (COPD) may be made difficult by the asthma-exacerbating effect of some antihypertensive drugs. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Beta blockers can cause increased bronchial obstruction and airway reactivity, and resistance to the effects of inhaled or oral beta receptor agonists (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"       terbutaline",
"      </a>",
"      ) in patients with asthma but not COPD. Even topical ophthalmic administration of nonselective beta blockers for the treatment of glaucoma has led to asthmatic exacerbations. Although the clinical effects of more &szlig;1-selective beta blockers on pulmonary function appear to be less severe, even &szlig;1-selective agents should be used with caution in patients with severe obstruction or markedly reduced baseline pulmonary function. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Beta blockers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Angiotensin converting enzyme (ACE) inhibitors are not first-line therapy in patients with asthma or COPD. Although exacerbation of airflow obstruction has not been a significant problem in asthmatic patients, several cases of worsening asthma have been described. However, these agents are",
"      <strong>",
"       not",
"      </strong>",
"      contraindicated in these disorders as long as the clinician is aware of the relatively uncommon complication of worsening airflow obstruction. An alternative, when it is desirable to block the renin-angiotensin system, is administration of an angiotensin II receptor blocker. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'ACE inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diuretics can be effectively used in asthmatics, but may cause serious hypokalemia if used concurrently with inhaled &szlig;2-receptor agonists, which drive potassium into the cells, and oral corticosteroids, which enhance urinary potassium excretion. In addition, diuretic-induced metabolic alkalosis can suppress ventilatory drive, potentially exacerbating the degree of hypoxemia. It is safest to administer only low thiazide doses (12.5 to 25 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      ) to nonedematous hypertensive patients with asthma or COPD (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diuretics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The calcium channel blockers (especially those of the dihydropyridine group, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"       nicardipine",
"      </a>",
"      ) are excellent agents for the treatment of hypertension in asthma. In addition to effectively lowering the blood pressure, they also have the theoretical advantages of opposing muscle contraction in tracheobronchial smooth muscle, inhibiting mast cell degranulation, and possibly reinforcing the bronchodilator effect of beta agonists. The use of a low-dose thiazide alone or with a calcium channel blocker represents the preferred regimen for the initial management of the hypertensive asthmatic. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Calcium channel blockers'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2021/abstract/1\">",
"      Benson MK, Berrill WT, Cruickshank JM, Sterling GS. A comparison of four beta-adrenoceptor antagonists in patients with asthma. Br J Clin Pharmacol 1978; 5:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2021/abstract/2\">",
"      Fraunfelder FT, Barker AF. Respiratory effects of timolol. N Engl J Med 1984; 311:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2021/abstract/3\">",
"      Rutten FH, Zuithoff NP, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2021/abstract/4\">",
"      Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blocker use in patients with reversible airway disease. Cochrane Database Syst Rev 2001; :CD002992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2021/abstract/5\">",
"      Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 2002; 137:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2021/abstract/6\">",
"      Ind PW, Dixon CM, Fuller RW, Barnes PJ. Anticholinergic blockade of beta-blocker-induced bronchoconstriction. Am Rev Respir Dis 1989; 139:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2021/abstract/7\">",
"      Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2021/abstract/8\">",
"      Bucknall CE, Neilly JB, Carter R, et al. Bronchial hyperreactivity in patients who cough after receiving angiotensin converting enzyme inhibitors. Br Med J (Clin Res Ed) 1988; 296:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2021/abstract/9\">",
"      Boulet LP, Milot J, Lampron N, Lacourci&egrave;re Y. Pulmonary function and airway responsiveness during long-term therapy with captopril. JAMA 1989; 261:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2021/abstract/10\">",
"      Kaufman J, Casanova JE, Riendl P, Schlueter DP. Bronchial hyperreactivity and cough due to angiotensin-converting enzyme inhibitors. Chest 1989; 95:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2021/abstract/11\">",
"      Lunde H, Hedner T, Samuelsson O, et al. Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ 1994; 308:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2021/abstract/12\">",
"      Tanaka H, Teramoto S, Oashi K, et al. Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma. Circulation 2001; 104:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2021/abstract/13\">",
"      Lipworth BJ, McDevitt DG, Struthers AD. Prior treatment with diuretic augments the hypokalemic and electrocardiographic effects of inhaled albuterol. Am J Med 1989; 86:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2021/abstract/14\">",
"      Wong CS, Pavord ID, Williams J, et al. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet 1990; 336:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2021/abstract/15\">",
"      Bear R, Goldstein M, Phillipson E, et al. Effect of metabolic alkalosis on respiratory function in patients with chronic obstructive lung disease. Can Med Assoc J 1977; 117:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2021/abstract/16\">",
"      Barnes PJ. Clinical studies with calcium antagonists in asthma. Br J Clin Pharmacol 1985; 20 Suppl 2:289S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2021/abstract/17\">",
"      Schwartzstein RS, Fanta CH. Orally administered nifedipine in chronic stable asthma. Comparison with an orally administered sympathomimetic. Am Rev Respir Dis 1986; 134:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2021/abstract/18\">",
"      Ann Twiss M, Harman E, Chesrown S, Hendeles L. Efficacy of calcium channel blockers as maintenance therapy for asthma. Br J Clin Pharmacol 2002; 53:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2021/abstract/19\">",
"      Patakas D, Maniki E, Tsara V, Dascalopoulou E. Nifedipine treatment of patients with bronchial asthma. J Allergy Clin Immunol 1987; 79:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2021/abstract/20\">",
"      Dinh Xuan AT, Matran R, Regnard J, et al. Comparative effects of rilmenidine and clonidine on bronchial responses to histamine in asthmatic subjects. Br J Clin Pharmacol 1988; 26:703.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3831 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.211.0.116-D41D634031-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_62_2021=[""].join("\n");
var outline_f1_62_2021=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13075016\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BETA BLOCKERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANGIOTENSIN RECEPTOR BLOCKERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIURETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CALCIUM CHANNEL BLOCKERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SYMPATHETIC BLOCKERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OTHER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13075016\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=related_link\">",
"      Causes of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32966?source=related_link\">",
"      Major side effects and safety of calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25224?source=related_link\">",
"      Renin-angiotensin system inhibition in the treatment of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15350?source=related_link\">",
"      Use of thiazide diuretics in patients with primary hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_62_2022="Paraneoplastic pemphigus multiple lesions";
var content_f1_62_2022=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F79192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F79192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Paraneoplastic pemphigus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bullae, erosions, and crusts are present on the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_62_2022=[""].join("\n");
var outline_f1_62_2022=null;
var title_f1_62_2023="Corticotropin injection gel: Drug information";
var content_f1_62_2023=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Corticotropin injection gel: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/48/1798?source=see_link\">",
"    see \"Corticotropin injection gel: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/33/14871?source=see_link\">",
"    see \"Corticotropin injection gel: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F154674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      H.P. Acthar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F154689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Systemic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F154675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Sudden withdrawal may lead to adrenal insufficiency or recurrent symptoms; tapering the dose prior to discontinuation may be necessary following prolonged administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute exacerbation of multiple sclerosis:",
"     </b>",
"     I.M., SubQ: 80-120 units/day for 2-3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      All other indications:",
"     </b>",
"     I.M., SubQ: 40-80 units every 24-72 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F154684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/33/14871?source=see_link\">",
"      see \"Corticotropin injection gel: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Sudden withdrawal may lead to adrenal insufficiency or recurrent symptoms; tapering the dose prior to discontinuation may be necessary following prolonged administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Infantile spasms:",
"     </b>",
"     Children &lt;2 years: I.M.: 75 units/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily for 2 weeks; followed by a gradual taper over a 2-week period. One suggested taper: 30 units/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose in the morning for 3 days, then 15 units/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose in the morning for 3 days, then 10 units/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose in the morning for 3 days, then 10 units/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every other morning for 6 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      All other indications:",
"     </b>",
"     Children &gt;2 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F154676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15795905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15795906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with caution in cirrhosis.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F154666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, gel:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     H.P. Acthar&reg;: 80 units/mL (5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F154653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11256533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     H.P. Acthar&reg; Gel is only available through specialty pharmacy distribution and not through traditional distribution sources (eg, wholesalers, retail pharmacies).  Hospitals wishing to acquire H.P. Acthar&reg; Gel should contact CuraScript Specialty Distribution (1-877-599-7748).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     After treatment is initiated, discharge or outpatient prescriptions should be submitted to the Acthar Support and Access Program (A.S.A.P.) in order to ensure an uninterrupted supply of the medication. The Acthar Referral/Prescription form is available online at file://www.acthar.com/files/Acthar-Prescription-Referral-Form.pdf.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Additional information is available for the A.S.A.P. at  file://www.acthar.com/healthcare-professionals/physician-patient-referrals or by calling 1-888-435-2284.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10961087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM231714.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM231714.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11329928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For I.M. or SubQ use; do not administer I.V. Warm gel before administration. Do not over-pressurize vial prior to withdrawing product.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F154667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute exacerbations of multiple sclerosis; infantile spasms; adjunctive therapy for exacerbations/acute episodes of rheumatic disorders (psoriatic arthritis, rheumatoid arthritis, juvenile idiopathic arthritis [JIA], ankylosing spondylitis); exacerbations or maintenance therapy for collagen diseases (systemic lupus erythematosus, systemic dermatomyositis); severe erythema multiforme; Stevens-Johnson syndrome; serum sickness; severe acute/chronic allergic and inflammatory ophthalmic disease (keratitis, iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation); symptomatic sarcoidosis; to induce diuresis for remission of proteinuria in patients with nephrotic syndrome without idiopathic uremia or due to lupus erythematosus",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3296141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Corticotropin may be confused with corticorelin, cosyntropin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F154687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adverse events associated with cortisol elevation; frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Blood pressure increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Behavioral changes, mood changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Fluid retention, glucose intolerance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Appetite increased, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Adverse events associated with infantile spasm treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cardiovascular: Hypertension (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Central nervous system: Seizure (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Miscellaneous: Infection (20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cardiovascular: Cardiac hypertrophy (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Central nervous system: Irritability (7%), pyrexia (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Endocrine &amp; metabolic: Cushingoid syndrome (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Gastrointestinal: Appetite decreased (3%), diarrhea (3%), vomiting (3%), weight gain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Respiratory: Nasal congestion (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Postmarketing and/or case reports (other adverse events associated with corticosteroids may also occur): Abdominal distension, allergic reactions, carbohydrate intolerance (infants), congestive heart failure, diaphoresis (adults), facial erythema, headache (adults), hirsutism, hypokalemic alkalosis (infants), intracranial hemorrhage (adults), muscle weakness, necrotizing angiitis (adults), pancreatitis (adults), reversible brain shrinkage (secondary to hypertension; infants), skin thinning (adults), subdural hematoma, ulcerative esophagitis, vertebral compression fractures (infants), vertigo (adults)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F154669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to proteins of porcine origin; scleroderma; osteoporosis; systemic fungal infections; ocular herpes simplex; peptic ulcer; recent surgery; congestive heart failure; uncontrolled hypertension; primary adrenocortical insufficiency; adrenocortical hyperfunction; infants with suspected congenital infections; concomitant administration of live or live attenuated vaccines; I.V. administration",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11329724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Symptoms of adrenal insufficiency may be difficult to detect in infants treated for infantile spasms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Electrolyte disturbances: May increase retention of sodium and wasting of calcium and potassium; sodium restriction and/or potassium supplementation may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Antibodies may develop following prolonged use and increase the risk of hypersensitivity reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Concomitant use of live or live attenuated vaccines is contraindicated; use caution with inactivated vaccines (response may be variable). Close observation is required in patients with latent tuberculosis (TB) and/or TB reactivity; if therapy is prolonged, chemoprophylaxis should be started.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Psychiatric disturbances: Corticosteroids may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular disease: Use with caution in patients hypertension; use has been associated with fluid retention and hypertension; use is contraindicated with uncontrolled hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, ulcerative colitis) due to perforation risk and GI bleeding; use is contraindicated with peptic ulcer disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred especially during initial treatment with corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged corticosteroid use. Consider routine eye exams in chronic users.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Osteoporosis: Use with caution in patients of any age at risk for osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures. Use is contraindicated in patients with osteoporosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: May affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Discontinuation of therapy: Withdraw therapy with gradual tapering of dose.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F154660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Systemic) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: May enhance the hypokalemic effect of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mitotane: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Corticosteroids (Systemic). Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir. Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6472588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Embryocidal effects may be observed following corticotropin use during pregnancy. Endogenous ACTH levels are increased during pregnancy. Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts; adverse events in the fetus/neonate have been noted in case reports following large doses of systemic corticosteroids during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6472590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6472591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Corticosteroids are excreted in human milk; information specific to corticotropin has not been located.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F154670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May increase renal loss of potassium, calcium, zinc, and vitamin C; may need to increase dietary intake or give supplements. May increase retention of sodium and water.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Acthar HP Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 units/mL (5 mL): $35857.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11329932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, weight; serum glucose, electrolytes; signs of adrenal insufficiency; signs of Cushing&rsquo;s syndrome; secondary ocular infections",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Following prolonged use: Bone mass density, growth in children, signs and symptoms of infection, cataract formation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Following discontinuation: Signs of infection, cardiac function, blood pressure, serum glucose, body weight, fecal blood",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acortan (DE);",
"     </li>",
"     <li>",
"      ACTH (AT);",
"     </li>",
"     <li>",
"      Acthar (IE, ZA);",
"     </li>",
"     <li>",
"      Acthelea (AR);",
"     </li>",
"     <li>",
"      Trofocortina (IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F154656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates the adrenal cortex to secrete adrenal steroids (including hydrocortisone, cortisone), androgenic substances, and a small amount of aldosterone",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F11329851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Half-life elimination: ACTH: 15 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ostensen M, &ldquo;Optimisation of Antirheumatic Drug Treatment in Pregnancy,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1994, 27(6):486-503.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/62/2023/abstract-text/7882637/pubmed\" id=\"7882637\" target=\"_blank\">",
"        7882637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pellock JM, Hrachovy R, Shinnar S, et al, \"Infantile Spasms: A U.S. Consensus Report,\"",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2010, 51(10):2175-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/62/2023/abstract-text/20608959/pubmed\" id=\"20608959\" target=\"_blank\">",
"        20608959",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pradat P, Robert-Gnansia E, Di Tanna GL, et al, &ldquo;First Trimester Exposure to Corticosteroids and Oral Clefts,&rdquo;",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(12):968-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/62/2023/abstract-text/14745915/pubmed\" id=\"14745915\" target=\"_blank\">",
"        14745915",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith R, &ldquo;Parturition,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 356(3):271-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/62/2023/abstract-text/17229954/pubmed\" id=\"17229954\" target=\"_blank\">",
"        17229954",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8885 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-294E67EF58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_62_2023=[""].join("\n");
var outline_f1_62_2023=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154674\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154689\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154675\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154684\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154676\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795905\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795906\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154666\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154653\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11256533\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961087\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11329928\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154667\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3296141\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154687\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154669\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11329724\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299095\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154660\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6472588\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6472590\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6472591\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154670\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570478\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11329932\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038588\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154656\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11329851\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8885\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8885|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/48/1798?source=related_link\">",
"      Corticotropin injection gel: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/33/14871?source=related_link\">",
"      Corticotropin injection gel: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_62_2024="Longitudinal melanonychia - thumbs";
var content_f1_62_2024=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64603%7EPEDS%2F54197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64603%7EPEDS%2F54197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Longitudinal melanonychia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple pigmented linear streaks on the nail are common in individuals in dark skin. The wart on the proximal nail fold of the thumb on the left is an unrelated finding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Longitudinal melanonychia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A biopsy of the nail matrix revealed a junctional melanocytic nevus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Schaffer JV, Bolognia JL. The clinical spectrum of pigmented lesions. Clin Plast Surg 2000; 27:391. Copyright &copy; 2000 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_62_2024=[""].join("\n");
var outline_f1_62_2024=null;
var title_f1_62_2025="Medical management of asymptomatic aortic stenosis in adults";
var content_f1_62_2025=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medical management of asymptomatic aortic stenosis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/62/2025/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/62/2025/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/62/2025/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/62/2025/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/62/2025/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/62/2025/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/62/2025/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 17, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In individuals with normal aortic valves, the effective area of valve opening equals the cross-sectional area of the left ventricular outflow tract, which is about 3.0 to 4.0 cm2 in adults. As aortic stenosis (AS) develops, a minimal valve gradient is present until the orifice area becomes less than half of normal. The natural history of AS therefore begins with a prolonged asymptomatic period associated with minimal mortality.",
"   </p>",
"   <p>",
"    Serial hemodynamic examinations in several studies show that progressive valve obstruction occurs in nearly all adults with calcific aortic valve disease once even mild valve obstruction is present (",
"    <a class=\"graphic graphic_figure graphicRef81124 \" href=\"UTD.htm?3/63/4094\">",
"     figure 1",
"    </a>",
"    ). Patients remain asymptomatic as aortic velocity increases and valve area decreases until the severity of obstruction results in an inadequate cardiac output with exercise leading to symptom onset. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30551?source=see_link&amp;anchor=H21857697#H21857697\">",
"     \"Natural history of aortic stenosis in adults\", section on 'Risk factors for progression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, symptoms in patients with AS and normal left ventricular systolic function rarely occur until the stenosis is severe as defined by valve area &lt;1.0 cm2, aortic jet velocity over 4.0",
"    <span class=\"nowrap\">",
"     m/sec,",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mean transvalvular gradient exceeds 40 mmHg (",
"    <a class=\"graphic graphic_table graphicRef65280 \" href=\"UTD.htm?17/33/17948\">",
"     table 1",
"    </a>",
"    ). However, many patients do not develop symptoms until even more severe valve obstruction is present, and some patients with less severe AS are symptomatic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\", section on 'Other clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The only effective treatment for severe symptomatic AS is valve replacement. In such patients who refuse or are not candidates for surgical intervention, therapeutic options are limited and of only marginal benefit. Percutaneous valve replacement may be an option for high risk patients in the future; this approach is currently being evaluated in clinical trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link\">",
"     \"Indications for valve replacement in aortic stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/43/41654?source=see_link\">",
"     \"Medical management of symptomatic aortic stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39411?source=see_link\">",
"     \"Percutaneous aortic valvotomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among asymptomatic patients, there are no medical therapies that have been proven to delay progression of the leaflet disease. Although retrospective studies of statin therapy were promising, a large randomized prospective study demonstrated that statin therapy does not prevent disease progression. However, many patients have concurrent cardiac conditions that require therapy, including hypertension, coronary heart disease, atrial fibrillation, and left ventricular dysfunction.",
"   </p>",
"   <p>",
"    The medical management of patients with asymptomatic AS will be reviewed here. The pathophysiology, natural history, and clinical features of AS, the timing of valve replacement for AS, and the treatment of patients with bicuspid aortic valve are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=see_link\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30551?source=see_link\">",
"     \"Natural history of aortic stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link\">",
"     \"Indications for valve replacement in aortic stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34377?source=see_link&amp;anchor=H2#H2\">",
"     \"Valvular heart disease in elderly adults\", section on 'Aortic stenosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7078?source=see_link\">",
"     \"Treatment of bicuspid aortic valve stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SERIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial echocardiography is useful for measurement of hemodynamic severity and monitoring disease progression. Echocardiography also provides information about left ventricular function and associated lesions, and is an important part of an integrated approach that includes a detailed history, a careful physical examination, and evaluation of exercise tolerance, in selected cases [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/1\">",
"     1",
"    </a>",
"    ]. Invasive hemodynamic evaluation is not recommended in asymptomatic patients. Patients should receive education about the expected disease course and symptoms that should be reported such as dyspnea, reduced exercise tolerance, exertional chest pain, lightheadedness, and syncope. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30551?source=see_link\">",
"     \"Natural history of aortic stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    valvular guideline recommendations for serial echocardiography in patients with AS (",
"    <a class=\"graphic graphic_table graphicRef80790 \" href=\"UTD.htm?14/18/14635\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef65280 \" href=\"UTD.htm?17/33/17948\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/1\">",
"     1",
"    </a>",
"    ]. In patients with mild AS, echocardiography is recommended every three to five years. In patients with moderate AS, echocardiography is recommended every one to two years. In patients with severe AS, echocardiography is recommended every year. Echocardiography is indicated earlier if there is a change in symptoms or signs suggestive of worsening cardiac status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREVENTION OF DISEASE PROGRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although preventative therapy has been sought, there currently are no treatments to prevent AS progression. Although rheumatic fever prophylaxis is important to prevent aortic and mitral valve disease initiation, there is no evidence that secondary prevention of rheumatic fever will prevent disease progression once aortic stenosis is present [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, rheumatic fever is now an uncommon disease in developed countries in which most cases of AS are due to calcific disease of a congenitally bicuspid or normal trileaflet aortic valve. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44070?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment and prevention of acute rheumatic fever\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hypercholesterolemia and statin therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with calcific AS of a trileaflet or bicuspid valve, it has been hypothesized that medical therapy might slow or prevent disease progression. In particular, there has been an association between AS progression and hypercholesterolemia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/3,4\">",
"     3,4",
"    </a>",
"    ] as well as an association between AS (usually supravalvular) and familial hypercholesterolemia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40774?source=see_link&amp;anchor=H5#H5\">",
"     \"Supravalvar aortic stenosis\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These observations suggest that the valve lesion in calcific AS or aortic valve sclerosis might be similar to atherosclerosis and that progression may be related to known atherosclerotic risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38279?source=see_link\">",
"     \"Aortic valve sclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Consistent with this hypothesis are the observations that aortic valve calcification and its progression are increased in patients with a serum LDL cholesterol &gt;130",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&gt;3.36",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/3\">",
"     3",
"    </a>",
"    ] and initial reports suggesting that statin therapy may slow the rate of hemodynamic progression of aortic valve sclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/7\">",
"     7",
"    </a>",
"    ] or AS [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/8-11\">",
"     8-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Statin trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following prospective studies evaluated the effect of statin therapy of the progression of AS in asymptomatic patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The SALTIRE trial enrolled 155 adults (mean age 68) with calcific AS (an aortic jet velocity of at least 2.5",
"      <span class=\"nowrap\">",
"       m/sec,",
"      </span>",
"      mean aortic valve area of 1.03 cm2) who were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      (80",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/12\">",
"       12",
"      </a>",
"      ]. The primary endpoints were the nonclinical endpoints of change in aortic jet velocity and aortic valve calcium score. At a median follow-up of 25 months, there was no difference in the rate of increase in aortic jet velocity (0.20",
"      <span class=\"nowrap\">",
"       m/sec",
"      </span>",
"      per year) or of progression of aortic valve calcification (22 percent per year).",
"     </li>",
"     <li>",
"      The nonrandomized RAAVE study prospectively assigned 121 consecutive patients with moderate to severe AS (aortic valve area 1.0 to 1.5 cm2; mean 1.21 cm2) to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      20 mg (61 patients) if their LDL-cholesterol was greater than 130",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.4",
"      <span class=\"nowrap\">",
"       mmol/L;",
"      </span>",
"      mean 160",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [4.1",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      or to no statin (60 patients) if their LDL-cholesterol was less than 130",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.4",
"      <span class=\"nowrap\">",
"       mmol/L,",
"      </span>",
"      mean 119",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [3.1",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/13\">",
"       13",
"      </a>",
"      ]. At a mean follow-up of 73 weeks, patients treated with rosuvastatin had significantly attenuated rates of deterioration in mean aortic valve area and aortic jet velocity compared to patients who did not receive rosuvastatin.",
"     </li>",
"     <li>",
"      The larger prospective SEAS study enrolled 1873 adults (mean age 68) with mild to moderate AS (mean aortic jet velocity 3.1",
"      <span class=\"nowrap\">",
"       m/s)",
"      </span>",
"      who were randomly assigned to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"       ezetimibe",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/14\">",
"       14",
"      </a>",
"      ]. At median follow-up of 52 months there was no difference between groups in the primary endpoint (35.3 versus 38.2 percent, hazard ratio 0.96; 95% CI 0.83 to 1.12). The primary end-point included cardiovascular death, aortic valve replacement, non-fatal myocardial infarction, hospitalized unstable angina pectoris, heart failure as a result of progression of AS, coronary artery bypass grafting, percutaneous coronary interventions, and non-hemorrhagic stroke. There was also no difference in the rate of aortic valve replacement (28 versus 30 percent) or in the rate of hemodynamic progression of AS with an increase in aortic jet velocity of",
"      <span class=\"nowrap\">",
"       0.62&plusmn;0.61m/s",
"      </span>",
"      per year in the placebo group compared to 0.61&plusmn;0.59",
"      <span class=\"nowrap\">",
"       m/s",
"      </span>",
"      per year in the treatment group. Although there were fewer ischemic events in the treatment group, this difference was only due to a lower rate of coronary bypass grafting at the time of aortic valve surgery so the clinical relevance of this finding is unclear. Overall, the results of the SEAS study do not provide convincing evidence that statin therapy affects the disease process in the valve leaflets [",
"      <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The ASTRONOMER trial enrolled a younger cohort (mean age 58) of 269 adults with mild to moderate AS (mean aortic jet velocity 3.2",
"      <span class=\"nowrap\">",
"       m/s,",
"      </span>",
"      mean age 48 years old) who were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      40 mg daily or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/16\">",
"       16",
"      </a>",
"      ]. Unlike earlier trials in which bicuspid aortic valve was rare (&lt;5 percent), a bicuspid valve was present in nearly half of the subjects in this study. At a mean follow-up of 3.5 years, the annualized increase in peak AS gradient was similar in the rosuvastatin and placebo groups (6.3&plusmn;6.9 versus 6.1&plusmn;8.2 mmHg).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Statin conclusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of statin therapy on progression of AS has been evaluated in prospective trials. At present, statin therapy solely for AS (ie, in the absence of coexisting atherosclerotic vascular disease or other indications) cannot be recommended. The potential effect of therapy earlier in the disease process (eg, on aortic sclerosis) has not been evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other potential preventative therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of other potential medical therapies to reduce progression, morbidity or mortality is unproven.",
"   </p>",
"   <p>",
"    The potential value of blockade of the renin angiotensin aldosterone system to prevent further changes in the valve leaflets in patients with AS has been examined in a few studies with conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/10,17-19\">",
"     10,17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective study of 2117 adults with aortic stenosis followed for a mean of 4.4 years found that those treated with angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) had a significantly lower all-cause mortality with an adjusted hazard ratio of 0.76 (95% CI 0.62-0.92) and fewer cardiovascular events with an adjusted hazard ratio of 0.77 (95% CI 0.65- 0.92) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/18\">",
"     18",
"    </a>",
"    ]. This observational study does not establish causation or provide information on the mechanism of potential benefit; potential mechanisms include prevention of progression in leaflet disease, effects on concurrent coronary atherosclerotic disease, lowering of systemic blood pressure, or beneficial effects on the left ventricular myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/20\">",
"     20",
"    </a>",
"    ]. Further studies will be needed to examine these possibilities. &nbsp;",
"   </p>",
"   <p>",
"    In a randomized prospective study of aldosterone blockade in 65 adults with asymptomatic moderate-severe AS,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    did not slow onset of LV systolic or diastolic dysfunction, decrease LV mass, or reduce progression of valve stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another potential target of therapy in AS includes treatment that affects tissue calcification. Only small studies suggesting a benefit of osteoporosis therapy are available to date [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ENDOCARDITIS PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a murmur due to aortic valve stenosis are considered to be at moderate risk for infective endocarditis (IE) and underlying AS is the predisposing factor for endocarditis in 10 to 18 percent of cases in published series. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14840?source=see_link\">",
"     \"Epidemiology, risk factors and microbiology of infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk is highest in those with a congenital bicuspid valve. The magnitude of risk was evaluated in a series of 2401 patients with congenital heart lesions who were followed prospectively; those with AS developed IE at a rate of 0.27 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/23\">",
"     23",
"    </a>",
"    ]. A higher peak gradient across the aortic valve was associated with a greater risk of IE. Although definitive data are lacking, clinical experience suggests that the risk of IE is lower in older patients with heavily calcified valves than in younger patients with less severe abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2007 American Heart Association (AHA) guidelines on the prevention of bacterial endocarditis (and the similar 2008",
"    <span class=\"nowrap\">",
"     AHA/ACC",
"    </span>",
"    guidelines) recommended that only patients with the highest risk of the development of endocarditis receive antimicrobial prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/25\">",
"     25",
"    </a>",
"    ]. Most patients with valvular heart disease, including those with AS or a bicuspid valve, are not included in this group and therefore do not require antimicrobial prophylaxis.(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with AS should be educated about the importance of optimal dental hygiene, including regular dental cleanings, to decrease the likelihood of sustained bacteremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is not uncommon in patients with AS and can attenuate some of the physical findings in AS. As an example, the carotid impulse may be brisk due to decreased vascular compliance, even though valve stenosis is present. In addition, there is experimental data suggesting that hypertension can result in underestimation of stenosis severity using pressure gradients or Doppler velocities, with valve area providing a more accurate measure of disease severity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with asymptomatic AS and hypertension, left ventricular afterload is elevated due to the \"double-load\" of increased systemic blood pressure and valve stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For this reason, many clinicians treat hypertension in patients with asymptomatic AS. Antihypertensive therapy should be started at low doses and titrated upward slowly with frequent monitoring and a greater degree of caution with more severe valve obstruction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some investigators advocate the use of angiotensin converting enzyme (ACE) inhibitors in patients with AS, given the benefits of these drugs on ventricular systolic and diastolic function. Although there is little clinical information to support this approach [",
"      <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/28\">",
"       28",
"      </a>",
"      ], small clinical studies have shown that ACE inhibitors are well tolerated in patients with mild to moderate AS [",
"      <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another possible option is a calcium channel blocker such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      although published data on use of this class of drugs in AS is lacking.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of hypertension in these patients is appropriate, although there have been concerns that such therapy might lead to adverse hemodynamic effects.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One concern is that a fixed obstruction at the valve level might blunt the expected rise in cardiac output as afterload is reduced (eg, with a vasodilator), possibly leading to hypotension and decreased coronary perfusion. However, we now know that in patients with mild to moderate and even severe asymptomatic AS, the valve leaflets are still flexible and the degree of leaflet opening can increase with increases in transvalvular flow rates [",
"      <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/30-33\">",
"       30-33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second concern is that a reduction in left ventricular volumes (eg, with a diuretic) in patients with a small, noncompliant, hypertrophied left ventricle could lead to a fall in cardiac output. Echocardiography can guide therapy by providing measures of left ventricular size but, in general, diuretics should be used cautiously and are not preferred for treatment of hypertension in patients with AS. There are no published data addressing this issue.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CORONARY ARTERY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a high prevalence of coronary artery disease (CAD) in adults with AS, as about 40 percent of patients undergoing valve replacement require concurrent coronary bypass grafting [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/34\">",
"     34",
"    </a>",
"    ]. The reasons for this high prevalence include the similar age and gender distribution and the shared risk factors of these two diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Risk factor reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with valvular heart disease, conventional coronary risk factors should be evaluated and treated based upon accepted guidelines for adults. Although there are no definitive data showing that risk factor reduction prevents disease progression in the valve leaflets, it is important to prevent concurrent coronary disease. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Hypercholesterolemia and statin therapy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5576?source=see_link\">",
"     \"Overview of primary prevention of coronary heart disease and stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Symptomatic CAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angina with effort occurs in about two-thirds of patients with severe AS. Approximately one-half of these patients have underlying coronary artery disease, while angina in the remaining patients is due to left ventricular hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition, preexisting valvular heart disease is present in about 5 percent of patients with an acute coronary syndrome, with about one-third having moderate to severe AS [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients with preexisting valve disease are more likely to present with heart failure and have worse outcomes than patients without valvular heart disease.",
"   </p>",
"   <p>",
"    It can be difficult to determine if the symptoms are due to the valve disease or to coexisting coronary disease. There is no absolute value of AS severity that correlates with the absence of symptoms. However, angina is unlikely to be due to valve obstruction when the valve area is greater than 1.2 cm2, jet velocity is less than 3.5",
"    <span class=\"nowrap\">",
"     m/sec,",
"    </span>",
"    and mean transvalvular gradient is less than 30 mmHg (",
"    <a class=\"graphic graphic_table graphicRef65280 \" href=\"UTD.htm?17/33/17948\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Among adults with any degree of AS and symptoms of angina, coronary angiography should be considered. Noninvasive tests for cardiac ischemia are less accurate than in patients with a normal aortic valve.",
"   </p>",
"   <p>",
"    The therapeutic approach varies with the findings from this evaluation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with angina due to coronary disease who have mild to moderate AS (",
"      <a class=\"graphic graphic_table graphicRef65280 \" href=\"UTD.htm?17/33/17948\">",
"       table 1",
"      </a>",
"      ) can be treated like any other patient with coronary disease with medical therapy and revascularization as appropriate. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=see_link\">",
"       \"Overview of the care of patients with stable ischemic heart disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=see_link\">",
"       \"Medical therapy versus revascularization in the management of stable angina pectoris\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with angina due to valve obstruction should undergo aortic valve replacement, since they are at high risk for mortality (",
"      <a class=\"graphic graphic_figure graphicRef81124 \" href=\"UTD.htm?3/63/4094\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link\">",
"       \"Indications for valve replacement in aortic stenosis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among patients with both severe AS and significant coronary disease, it is difficult to determine which condition contributes to the anginal symptoms. In this setting, surgical intervention for treatment of both conditions is appropriate [",
"      <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/34\">",
"       34",
"      </a>",
"      ]. Percutaneous coronary intervention with stenting may be considered if the patient is at high risk for surgery, but symptoms will persist if valve obstruction is the cause.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The issues of aortic valve replacement at the time of coronary artery bypass graft surgery in adults with asymptomatic AS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link\">",
"     \"Indications for valve replacement in aortic stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PHYSICAL ACTIVITY AND EXERCISE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The marked increase in cardiac output with exercise can, in patients with AS, lead to increases in the valve gradient and left ventricular systolic pressure. The magnitude of this effect varies with the severity of the AS (",
"    <a class=\"graphic graphic_table graphicRef65280 \" href=\"UTD.htm?17/33/17948\">",
"     table 1",
"    </a>",
"    ) and with the intensity and type of exercise.",
"   </p>",
"   <p>",
"    Taking these factors into account, specific recommendations for participation in competitive sports in patients with AS were made by the 36th Bethesda Conference; the recommendations varied with intensity and type of exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with mild AS can participate in all competitive sports, but serial evaluation of the severity of the disease should be performed at least yearly.",
"     </li>",
"     <li>",
"      Patients with asymptomatic moderate AS can participate in low-intensity competitive sports (class IA) and selected patients can participate in low and moderate static or dynamic competitive sports (class IA, IB, and IIA) (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 2",
"      </a>",
"      ) if they meet the following criteria: exercise testing to at least the level of activity attained during sports reveals satisfactory exercise capacity with a normal blood pressure response and without symptoms, ST segment depression, or ventricular tachyarrhythmias.",
"     </li>",
"     <li>",
"      Patients with asymptomatic moderate AS who have supraventricular tachycardia or multiple or complex tachyarrhythmias at rest or with exercise should only participate in low-intensity competitive sports (class IA) (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with severe AS or symptomatic patients with moderate AS should not participate in any competitive sports.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recommendations for exercise in patients with bicuspid aortic valves who have aortic root dilatation are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7078?source=see_link\">",
"     \"Treatment of bicuspid aortic valve stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ATRIAL FIBRILLATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation can occur in patients with AS and, in a previously asymptomatic patient, may precipitate overt heart failure. Because of the noncompliant left ventricle, there is a relative shift of left ventricular filling to the later part of diastole with a greater dependence upon atrial contraction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=see_link&amp;anchor=H7#H7\">",
"     \"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm\", section on 'Atrial systole'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Atrial fibrillation in patients with AS can be managed using a similar approach as in patients without AS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link\">",
"     \"Overview of atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     HEART FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Valve replacement is indicated in patients with severe AS who develop symptomatic heart failure (",
"    <a class=\"graphic graphic_figure graphicRef81124 \" href=\"UTD.htm?3/63/4094\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link\">",
"     \"Indications for valve replacement in aortic stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A potential diagnostic problem is that in patients with heart failure who have left ventricular systolic dysfunction and an abnormal aortic valve, the transvalvular pressure gradient may be low even with severe valve obstruction. The pathophysiology and evaluation of patients with low gradient aortic stenosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/14/35047?source=see_link\">",
"     \"Low gradient aortic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the evaluation shows that the valve stenosis is only mild to moderate, medical treatment of heart failure is indicated rather than valve replacement. Such therapy includes vasodilator therapy, optimization of volume status, and beta blockers, with careful dose titration and frequent monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/27,39\">",
"     27,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of symptomatic patients with severe AS, including critically ill patients, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/43/41654?source=see_link\">",
"     \"Medical management of symptomatic aortic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     BETA BLOCKERS FOR AORTIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most adults with a bicuspid aortic valve eventually develop aortic stenosis, with a smaller number developing severe regurgitation; a bicuspid valve accounts for about 50 percent of aortic valve replacements in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/40\">",
"     40",
"    </a>",
"    ]. Some patients with a bicuspid valve also have an associated aortopathy with an increased risk of progressive dilatation of the aortic root",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ascending aorta, and an increased risk of aortic dissection. As a result, monitoring of patients with bicuspid AS includes assessment for and monitoring of aortic dilation, if present (",
"    <a class=\"graphic graphic_table graphicRef82459 \" href=\"UTD.htm?23/34/24107\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines (with 2008 focused update) on the management of valvular heart disease concluded that the weight of evidence or opinion was in favor of the administration of beta blockers to patients with a bicuspid aortic valve and an aortic root diameter greater than 40 mm (normal &le;35 mm) who are not candidates for surgery and do not have moderate or severe aortic regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/1\">",
"     1",
"    </a>",
"    ]. Lower threshold values for aortic root diameter may be considered in men or women of small stature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     NONCARDIAC SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical deterioration can occur in patients with asymptomatic AS during the hemodynamic stress associated with noncardiac surgery (as well as other stresses such as infection, anemia, or pregnancy). Most adverse events occur because the diagnosis of AS was not known to the surgical team. Preoperative echocardiographic evaluation of any murmur that is not clearly benign should avoid this problem. The risk of surgery and management of such patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/14/13544?source=see_link\">",
"     \"Noncardiac surgery in patients with aortic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of pregnant women with congenital AS is discussed elsewhere. These women have a higher prevalence of unicuspid disease, since bicuspid valves are usually not stenotic until later in life [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2025/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27032?source=see_link\">",
"     \"Pregnancy in women with a bicuspid aortic valve\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\", section on 'Relative frequency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/53/36690?source=see_link\">",
"       \"Patient information: Aortic stenosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22595795\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary goals in treating patients with asymptomatic AS is monitoring of disease, early detection of symptom onset, and treatment of conventional cardiovascular risk factors. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Serial evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with asymptomatic AS, there are no medical therapies that have been proven to delay progression of disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prevention of disease progression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with mild AS, echocardiography is recommended every three to five years. In patients with moderate AS, echocardiography is recommended every one to two years. In patients with severe asymptomatic AS, echocardiography is recommended every year. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Serial evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with asymptomatic AS and hypertension, the ventricle is exposed to a \"double-load\" of increased systemic blood pressure and valve stenosis. Treatment of hypertension in these patients is appropriate, although therapy will need to be closely monitored and carefully titrated. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with aortic valve disease, conventional coronary risk factors should be evaluated and treated based upon accepted guidelines for adults. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Risk factor reduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since clinical deterioration can occur in patients with asymptomatic AS during the hemodynamic stress associated with noncardiac surgery, preoperative evaluation (including echocardiography of murmurs suggestive of AS) is indicated. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Noncardiac surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Onset of symptoms in patients with severe AS is an indication for aortic valve surgery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link\">",
"       \"Indications for valve replacement in aortic stenosis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/43/41654?source=see_link\">",
"       \"Medical management of symptomatic aortic stenosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39411?source=see_link\">",
"       \"Percutaneous aortic valvotomy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/1\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/2\">",
"      Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2009; 119:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/3\">",
"      Pohle K, M&auml;ffert R, Ropers D, et al. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation 2001; 104:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/4\">",
"      Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation 2000; 101:2497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/5\">",
"      Rallidis L, Naoumova RP, Thompson GR, Nihoyannopoulos P. Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolaemia. Heart 1998; 80:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/6\">",
"      Agmon Y, Khandheria BK, Meissner I, et al. Aortic valve sclerosis and aortic atherosclerosis: different manifestations of the same disease? Insights from a population-based study. J Am Coll Cardiol 2001; 38:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/7\">",
"      Shavelle DM, Takasu J, Budoff MJ, et al. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 2002; 359:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/8\">",
"      Novaro GM, Tiong IY, Pearce GL, et al. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation 2001; 104:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/9\">",
"      Bellamy MF, Pellikka PA, Klarich KW, et al. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 2002; 40:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/10\">",
"      Rosenhek R, Rader F, Loho N, et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004; 110:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/11\">",
"      Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 2001; 88:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/12\">",
"      Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005; 352:2389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/13\">",
"      Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007; 49:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/14\">",
"      Rosseb&oslash; AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/15\">",
"      Otto CM. Calcific aortic stenosis--time to look more closely at the valve. N Engl J Med 2008; 359:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/16\">",
"      Chan KL, Teo K, Dumesnil JG, et al. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010; 121:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/17\">",
"      O'Brien KD, Probstfield JL, Caulfield MT, et al. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med 2005; 165:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/18\">",
"      Nadir MA, Wei L, Elder DH, et al. Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis. J Am Coll Cardiol 2011; 58:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/19\">",
"      Stewart RA, Kerr AJ, Cowan BR, et al. A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis. Am Heart J 2008; 156:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/20\">",
"      Aurigemma GP, Keaney JF Jr. Renin-angiotensin system inhibition for aortic stenosis \"A II, Brut&eacute;?\". J Am Coll Cardiol 2011; 58:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/21\">",
"      Skolnick AH, Osranek M, Formica P, Kronzon I. Osteoporosis treatment and progression of aortic stenosis. Am J Cardiol 2009; 104:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/22\">",
"      Innasimuthu AL, Katz WE. Effect of bisphosphonates on the progression of degenerative aortic stenosis. Echocardiography 2011; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/23\">",
"      Gersony WM, Hayes CJ, Driscoll DJ, et al. Bacterial endocarditis in patients with aortic stenosis, pulmonary stenosis, or ventricular septal defect. Circulation 1993; 87:I121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/24\">",
"      Roberts WC, Oluwole BO, Fernicola DJ. Comparison of active infective endocarditis involving a previously stenotic versus a previously nonstenotic aortic valve. Am J Cardiol 1993; 71:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/25\">",
"      Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/26\">",
"      Kadem L, Dumesnil JG, Rieu R, et al. Impact of systemic hypertension on the assessment of aortic stenosis. Heart 2005; 91:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/27\">",
"      Zile MR, Gaasch WH. Heart failure in aortic stenosis - improving diagnosis and treatment. N Engl J Med 2003; 348:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/28\">",
"      Routledge HC, Townend JN. ACE inhibition in aortic stenosis: dangerous medicine or golden opportunity? J Hum Hypertens 2001; 15:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/29\">",
"      O'Brien KD, Zhao XQ, Shavelle DM, et al. Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function. J Investig Med 2004; 52:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/30\">",
"      Badano L, Cassottano P, Bertoli D, et al. Changes in effective aortic valve area during ejection in adults with aortic stenosis. Am J Cardiol 1996; 78:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/31\">",
"      Bermejo J, Garc&iacute;a-Fern&aacute;ndez MA, Torrecilla EG, et al. Effects of dobutamine on Doppler echocardiographic indexes of aortic stenosis. J Am Coll Cardiol 1996; 28:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/32\">",
"      Burwash IG, Forbes AD, Sadahiro M, et al. Echocardiographic volume flow and stenosis severity measures with changing flow rate in aortic stenosis. Am J Physiol 1993; 265:H1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/33\">",
"      Chambers JB, Sprigings DC, Cochrane T, et al. Continuity equation and Gorlin formula compared with directly observed orifice area in native and prosthetic aortic valves. Br Heart J 1992; 67:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/34\">",
"      Kvidal P, Bergstr&ouml;m R, H&ouml;rte LG, St&aring;hle E. Observed and relative survival after aortic valve replacement. J Am Coll Cardiol 2000; 35:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/35\">",
"      Julius BK, Spillmann M, Vassalli G, et al. Angina pectoris in patients with aortic stenosis and normal coronary arteries. Mechanisms and pathophysiological concepts. Circulation 1997; 95:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/36\">",
"      Hasdai D, Lev EI, Behar S, et al. Acute coronary syndromes in patients with pre-existing moderate to severe valvular disease of the heart: lessons from the Euro-Heart Survey of acute coronary syndromes. Eur Heart J 2003; 24:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/37\">",
"      Bonow RO, Cheitlin MD, Crawford MH, Douglas PS. Task Force 3: valvular heart disease. J Am Coll Cardiol 2005; 45:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/38\">",
"      Mitchell JH, Haskell W, Snell P, Van Camp SP. Task Force 8: classification of sports. J Am Coll Cardiol 2005; 45:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/39\">",
"      Chockalingam A, Venkatesan S, Subramaniam T, et al. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS). Am Heart J 2004; 147:E19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2025/abstract/40\">",
"      Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation 2005; 111:920.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8117 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-294E67EF58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_62_2025=[""].join("\n");
var outline_f1_62_2025=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22595795\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SERIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREVENTION OF DISEASE PROGRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hypercholesterolemia and statin therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Rationale",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Statin trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Statin conclusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other potential preventative therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ENDOCARDITIS PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CORONARY ARTERY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Symptomatic CAD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PHYSICAL ACTIVITY AND EXERCISE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ATRIAL FIBRILLATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      HEART FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      BETA BLOCKERS FOR AORTIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      NONCARDIAC SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22595795\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8117\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8117|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/63/4094\" title=\"figure 1\">",
"      Natural history of AS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/51/29489\" title=\"figure 2\">",
"      Classification exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8117|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/33/17948\" title=\"table 1\">",
"      Severity of AS in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/18/14635\" title=\"table 2\">",
"      ACC AHA echo aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/34/24107\" title=\"table 3\">",
"      Bicuspid AV dilated asc aorta",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38279?source=related_link\">",
"      Aortic valve sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=related_link\">",
"      Clinical features and evaluation of aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=related_link\">",
"      Clinical manifestations and diagnosis of bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14840?source=related_link\">",
"      Epidemiology, risk factors and microbiology of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=related_link\">",
"      Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=related_link\">",
"      Indications for valve replacement in aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/14/35047?source=related_link\">",
"      Low gradient aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/43/41654?source=related_link\">",
"      Medical management of symptomatic aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=related_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30551?source=related_link\">",
"      Natural history of aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/14/13544?source=related_link\">",
"      Noncardiac surgery in patients with aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5576?source=related_link\">",
"      Overview of primary prevention of coronary heart disease and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=related_link\">",
"      Overview of the care of patients with stable ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/53/36690?source=related_link\">",
"      Patient information: Aortic stenosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39411?source=related_link\">",
"      Percutaneous aortic valvotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27032?source=related_link\">",
"      Pregnancy in women with a bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40774?source=related_link\">",
"      Supravalvar aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44070?source=related_link\">",
"      Treatment and prevention of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7078?source=related_link\">",
"      Treatment of bicuspid aortic valve stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34377?source=related_link\">",
"      Valvular heart disease in elderly adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_62_2026="Penetrating neck injuries";
var content_f1_62_2026=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Penetrating neck injuries",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/62/2026/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/62/2026/contributors\">",
"     Kim Newton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/62/2026/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/62/2026/contributors\">",
"     Maria E Moreira, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/62/2026/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/62/2026/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/62/2026/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/62/2026/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penetrating neck injuries (PNIs) refer to neck injuries induced by gunshot wounds, stab wounds, or penetrating debris, such as glass or shrapnel. Before World War II, all PNIs were treated expectantly and mortality rates were as high as 35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/1\">",
"     1",
"    </a>",
"    ]. In an attempt to reduce the high death rates associated with PNIs, a mandatory surgical approach was adopted, even for stable patients. This approach reduced mortality rates [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mandatory surgical exploration remained widely accepted well into the 1990s, when it became obvious that while the mortality rate was low, the rate of negative surgical explorations was unacceptably high (58 percent in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/3\">",
"     3",
"    </a>",
"    ]. From this observation came the concept of selective surgical management, which offers a spectrum of diagnostic approaches.",
"   </p>",
"   <p>",
"    PNI, defined by platysma violation, comprises a sizable number of traumatic injuries in adults and remains a difficult management issue [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/1\">",
"     1",
"    </a>",
"    ]. While surgical intervention is necessary in approximately 15 to 20 percent of PNI cases, the management of stable patients remains a source of debate [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of PNIs will be reviewed here. Traumatic shock and other trauma topics are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=see_link\">",
"     \"Initial evaluation and management of shock in adult trauma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penetrating neck injury (PNI) comprises 5 to 10 percent of traumatic injuries in adults and is caused primarily by bullets, knives, and other impaling objects (eg, shrapnel, glass) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/6\">",
"     6",
"    </a>",
"    ]. Wounds caused by low velocity guns or impaling objects tend to cause fewer aerodigestive and vascular injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/7\">",
"     7",
"    </a>",
"    ]. High velocity injuries carry a greater likelihood of serious injury and death [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/8\">",
"     8",
"    </a>",
"    ]. Overall mortality ranges from 3 to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PNI is categorized by anatomic zones, which are described below. Mortality in patients with PNI appears to be highest with zone I injuries (below the cricoid cartilage) because of the nature of the vascular injuries and the risks inherent in more difficult surgical explorations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/1\">",
"     1",
"    </a>",
"    ]. Exsanguination is the most common cause of death, and the carotid artery is the structure most often involved [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The incidence of carotid artery injury in PNI ranges from 6 to 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Anatomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One review of studies published from 1963 through 1990 included over 2495 patients with PNI and reported that zone II injuries are most common, followed by zone I then zone III [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/2\">",
"     2",
"    </a>",
"    ]. According to this review, the aerodigestive tract was injured most frequently. Ten percent of such patients had laryngeal or tracheal injury and 9.6 percent had pharyngeal or esophageal wounds. Vascular injuries were also common: 9 percent had internal jugular vein injury and 6.7 percent carotid artery injury. Spinal cord injury occurred in 3 percent. Less common injuries included the subclavian artery (2.2 percent), vertebral artery (1.3 percent), brachial plexus (1.9 percent), cranial nerves 9 and 10 (0.9 percent), and the thoracic duct (&lt;0.1 percent).",
"   </p>",
"   <p>",
"    Mortality from penetrating laryngotracheal trauma is reported to be 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/5\">",
"     5",
"    </a>",
"    ]. Mortality from pharyngoesophageal injuries is as high as 22 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. Unstable cervical spinal column injuries are rare following PNI [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neck anatomy is complex with aerodigestive and neurovascular structures confined to a small area.",
"   </p>",
"   <p>",
"    Clinicians generally describe penetrating neck trauma according to the zone of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/15\">",
"     15",
"    </a>",
"    ]. The neck is divided into three zones (",
"    <a class=\"graphic graphic_figure graphicRef52642 \" href=\"UTD.htm?13/45/14034\">",
"     figure 1",
"    </a>",
"    ). Zone I is the most caudal and includes the base of the neck and thoracic inlet. It extends from the sternal notch and clavicles to the cricoid cartilage. Zone I contains the thoracic outlet vasculature, vertebral and proximal carotid arteries, apices of the lungs, trachea, esophagus, spinal cord, and thoracic duct. Zone II (midneck) continues cephalad from the cricoid cartilage to the angle of the mandible, and contains the jugular veins, vertebral and common carotid arteries, and internal and external branches of the carotid arteries, as well as the trachea, esophagus, larynx, and spinal cord. Zone III (upper neck) includes the region above the angle of the mandible up to the base of the skull and contains the pharynx along with the jugular veins, vertebral arteries, and the distal portion of the internal carotid arteries. Zone designation carries implications for management and prognosis. Zone I injuries can involve the mediastinum and control of vascular injuries can be difficult. Zone III vascular injuries, especially those more cephalad, pose a surgical challenge.",
"   </p>",
"   <p>",
"    Penetrating injuries can transgress zone boundaries depending upon the implement or projectile and its angle of penetration. Therefore, clinicians must consider the possibility of injuries within zones other than that containing the entry wound. As an example, PNI sustained from a downward stab wound that enters the anterior neck in zone II may also injure the lungs and mediastinal structures.",
"   </p>",
"   <p>",
"    The neck can also be divided into triangles (",
"    <a class=\"graphic graphic_figure graphicRef74489 \" href=\"UTD.htm?41/25/42388\">",
"     figure 2",
"    </a>",
"    ). The anterior triangle is bordered anteriorly by the midline, posteriorly by the sternocleidomastoid muscle, and superiorly by the lower edge of the mandible. The posterior triangle is located within the boundaries of the sternocleidomastoid muscle anteriorly, the clavicle inferiorly, and the anterior border of the trapezius muscle posteriorly. Most vital structures are located in the anterior triangle. Trauma to the posterior triangle, excluding the spine, carries a much lower likelihood of significant injury.",
"   </p>",
"   <p>",
"    The neck has several fascial compartments. These compartments can help to contain bleeding from some vascular injuries. The most superficial fascia is located just below the skin, superficial to the platysma muscle. The platysma muscle, which originates in the upper chest, extends superiorly over the clavicles and covers the anterolateral neck before attaching to the lower facial muscles. Documentation of platysmal violation and zone of injury is essential when evaluating patients with PNI. When the platysma is violated, a careful search for aerodigestive and neurovascular injury must be performed.",
"   </p>",
"   <p>",
"    Deep to the platysma is the deep cervical fascia. This divides into prevertebral, pretracheal, and investing layers. The pretracheal fascia attaches to the cartilaginous structures in the anterior neck (cricoid and larynx) before coursing inferiorly and deep to the sternum, ultimately inserting onto the sternum and pericardium. The location of this fascia allows spillage of contents from an injured esophagus into the mediastinum. The carotid sheath is composed of all three layers of the deep cervical fascia. Within this sheath lie the carotid artery, internal jugular vein, and vagus nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/16\">",
"     16",
"    </a>",
"    ]. One sheath lies lateral to each side of the midline trachea. The esophagus is directly posterior to the trachea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MECHANISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penetrating neck injuries commonly occur from guns, knives, and other impaling objects. Gunshot wounds are further divided into high and low velocity injuries. Bone penetration requires a velocity of approximately 350 feet per second (107 meters per second). Because low velocity weapons (eg, .22-caliber guns, other handguns, air guns) do not typically penetrate bone, they tend to produce a more erratic path through soft tissue, following tissue planes. Military weapons and hunting rifles can fire at speeds over 2000 to 3000 feet per second (610 to 910 meters per second) and follow a more direct, predictable course through bone and soft tissue. High velocity weapons can cause injury far from the bullet track through the release of high energy with impact (ie, blast effect). Clinicians may underestimate tissue damage from this effect [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREHOSPITAL CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H932869\">",
"    <span class=\"h2\">",
"     General management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any patient with a penetrating neck injury (PNI) can decompensate rapidly and should be transported immediately to the nearest trauma center. These patients often require emergency surgical intervention. Impaled objects should",
"    <strong>",
"     NOT",
"    </strong>",
"    be removed in the field. General prehospital management of the trauma patient is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17482?source=see_link\">",
"     \"Prehospital care of the adult trauma patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Airway management in the patient with PNI can be difficult, and is discussed in detail below. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Airway management'",
"    </a>",
"    below.) Orotracheal intubation is the primary approach to airway stabilization when a definitive airway is required immediately. Bag mask ventilation (BMV) can be used during transport. BMV can become problematic, however, if an airway injury is present. BMV can force air into soft tissue planes leading to anatomical distortion.",
"   </p>",
"   <p>",
"    During transport, breath sounds should be auscultated and vital signs assessed frequently. Hypotension, tachypnea, unilaterally diminished breath sounds, and subcutaneous emphysema raise suspicion for a tension pneumothorax. Paramedics should perform needle thoracostomy if the patient is unstable and tension pneumothorax is suspected.",
"   </p>",
"   <p>",
"    In general, patients should be allowed to assume a position that enables them to breathe. This is particularly true if hemorrhage is extensive and creates breathing difficulty.",
"   </p>",
"   <p>",
"    Place a large bore IV (eg, 14 gauge) in the arm opposite the injury if possible and control active bleeding with direct pressure. Patients with bubbling or sucking neck wounds should ideally be placed head-down (eg, Trendelenburg position) on their left side to prevent potential vascular air embolism. Gauze impregnated with petroleum jelly should be applied to the wound to prevent venous air embolus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H932876\">",
"    <span class=\"h2\">",
"     Cervical spine immobilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical spine (C-spine) immobilization should be applied if clinical findings (eg, hemiplegia) suggest spinal cord injury. However, such injuries are uncommon with penetrating neck trauma (particularly stab wounds) and immobilization may hinder management in some cases by impeding visualization of the airway or obscuring other injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/14,18-21\">",
"     14,18-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We agree with the practice guidelines from the Eastern Association for the Surgery of Trauma (EAST) which state that C-spine immobilization is only necessary when a neurologic deficit is present or a proper physical examination cannot be performed (eg, unconscious patient) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/22\">",
"     22",
"    </a>",
"    ]. A systematic review performed by the Prehospital Trauma Life Support Program concurs with this approach and goes on to emphasize that spine immobilization must not be performed at the expense of an accurate examination or the treatment of life-threatening conditions in a patient with penetrating trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/23\">",
"     23",
"    </a>",
"    ]. Patients in need of C-spine immobilization who have difficulty breathing due to hemorrhage may need their stretcher placed on its side, or may need to sit upright while C-spine precautions are maintained as best as possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Laryngotracheal injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laryngotracheal injuries are predominantly confined to the cervical trachea. Such injuries can result in respiratory distress, stridor, subcutaneous air, hemoptysis, odynophagia, dysphonia, or anterior neck tenderness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Vascular injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular injuries can involve the carotid artery (common, internal, and external), the subclavian and vertebral arteries, and the vertebral, brachiocephalic, and jugular (internal and external) veins. Vascular wounds are not always obvious and if missed may lead to delayed complications, such as delayed rupture and arteriovenous fistula. Look for obvious and subtle signs of injury. Obvious signs include severe bleeding, decreased or absent peripheral pulses, global or focal neurologic deficits (eg, stroke), expanding hematoma, and bruits or thrills. Subtle signs include nonexpansile hematomas, mild bleeding, and transient hypotension that respond to fluid resuscitation. Intact pulses do",
"    <strong>",
"     NOT",
"    </strong>",
"    negate the possibility of vascular injury. Global neurologic deficits (eg, hemiplegia) can be caused by a vascular injury. A patient with a normal physical examination who is otherwise asymptomatic is unlikely to have sustained a surgical vascular lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pharyngoesophageal injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharyngoesophageal injuries are uncommon but are associated with high morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. They can be difficult to detect clinically and appear to be the leading cause of delayed death from neck trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/22,25,26\">",
"     22,25,26",
"    </a>",
"    ]. Clinicians should aggressively search for pharyngoesophageal injuries in patients with any suggestive signs using appropriate ancillary studies. There are no pathognomonic signs of esophageal injury, but dysphagia, blood in the saliva, hematemesis, and subcutaneous air suggest the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Emergency management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Nervous system injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penetrating neck injury (PNI) can involve the central nervous system (spinal cord) or the peripheral nervous system (cranial nerves including VII though XII, sympathetic chain, peripheral nerve roots, brachial plexus). Spinal cord injury is uncommon following low velocity PNI (eg, stabbing). (See",
"    <a class=\"local\" href=\"#H932876\">",
"     'Cervical spine immobilization'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    High spinal cord injury can result in neurogenic shock with hypotension and bradycardia. Partial cord lesions create variable combinations of motor and sensory deficits depending on the lesion. The Brown-Sequard syndrome (lateral hemisection of the spinal cord) results in ipsilateral hemiplegia and contralateral loss of pain and temperature sensation. Hemiplegia occurs at the level of the injury while the sensory deficits occur one to two levels superiorly. Injury to the anterior spinal cord produces bilateral paralysis or motor deficits of variable severity, reflex changes, and bilateral loss of pain and temperature sensation, but proprioception is preserved. Dorsal spinal cord injury produces muscle flaccidity, hyporeflexia, ataxia, and loss of proprioception.",
"   </p>",
"   <p>",
"    Peripheral or cranial nerve (CN) injuries may not be obvious unless a careful neurologic examination is performed. If possible, assess the patient's speech (CN IX, X, XII), movement of the palate (CN IX, X) and tongue (CN XII), and shoulder shrug (CN XI). These functions involve the cranial nerves most frequently injured.",
"   </p>",
"   <p>",
"    Horner's syndrome occurs with injury to the sympathetic chain, and produces ipsilateral miosis with ptosis of the upper eyelid and anhidrosis of the ipsilateral side of the face. It is seen most commonly with zone I injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EMERGENCY MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Initial evaluation and interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with penetrating neck injury (PNI) may appear stable but can decompensate rapidly. Surgical consultation should be obtained for all PNIs unless the wounds are determined to be superficial. An algorithm for wounds that penetrate the platysma is provided (",
"    <a class=\"graphic graphic_algorithm graphicRef51111 \" href=\"UTD.htm?11/21/11615\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Penetrating neck trauma must be approached systematically. Immediately assess the airway of any patient with PNI. Assessment can be difficult, particularly deciding whether the patient needs early intubation. Although no consensus exists, most experts advocate immediate intubation in patients with evidence of significant injury or respiratory difficulty (eg, subcutaneous air, airway compromise, significant bleeding or hematoma, voice alteration, stridor) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Airway management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Once the airway has been stabilized, inspect and auscultate the chest. Zone I injuries can cause damage to intrathoracic structures (eg, lung). Moreover, multiple zones may be involved, creating injuries in both the neck and chest. Unilaterally decreased breath sounds or palpable subcutaneous emphysema suggests pneumothorax. The neck zones are defined above.",
"   </p>",
"   <p>",
"    Next, assess pulses and vital signs. Apply direct pressure to bleeding wounds. In almost all cases, the wound should not be explored in the emergency department (ED). For persistent, life-threatening bleeding from a neck wound that does not stop with direct pressure, the clinician can insert a Foley catheter into the wound and fill the balloon with 10 to 15 mL of saline or until resistance is felt [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. This may temporarily tamponade bleeding until definitive treatment is available. If bleeding is severe, neither direct pressure nor a Foley catheter effectively controls the hemorrhage, and no surgeon is available, the emergency clinician may have no choice but to attempt to explore the wound and control bleeding by other means (eg, placing a clamp).",
"   </p>",
"   <p>",
"    Place patients on a cardiac monitor and pulse oximetry, and provide supplemental oxygen. Place two large bore (eg, 14 gauge) IV lines. The IV lines should be placed contralateral to the injury if possible because ipsilateral venous injuries may exist.",
"   </p>",
"   <p>",
"    Type and cross-match blood in preparation for transfusion and obtain blood samples for testing. The blood tests to obtain vary with clinical circumstance, but usually include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prothrombin time (PT) with international normalized ratio (INR) and activated partial thromboplastin time (PTT)",
"     </li>",
"     <li>",
"      Serial hemoglobins",
"     </li>",
"     <li>",
"      Blood urea nitrogen and serum creatinine and electrolytes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Traumatic arrest in the ED in a patient with a PNI is an indication for emergency thoracotomy. Potential causes of arrest include hemorrhagic shock, tension pneumothorax, airway compromise, and air embolism. ED thoracotomy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=see_link\">",
"     \"Initial evaluation and management of shock in adult trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unstable patients with active hemorrhage are managed in the operating room. Those with findings suggestive of major injury require further evaluation, which may include angiography with embolization. They may be taken to the angiography suite, operating room, or intensive care unit (ICU). Stable patients with less obvious signs of injury are often evaluated further in the ED. The signs of injury are described above. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Stable patients should be closely monitored throughout their evaluation. Perform frequent reexaminations and look closely for signs of injury to the larynx, trachea, pharynx, esophagus, carotid arteries, jugular veins, lower cranial nerves, brachial plexus, and spinal cord.",
"   </p>",
"   <p>",
"    Although careful physical examination identifies most arterial wounds, it does not detect some important injuries, particularly those of the esophagus. Venous injuries can also be missed. Left neck trauma can rarely involve the thoracic duct. Although uncommon, the thyroid gland can be injured, as can other submandibular glands. Lower neck wounds can cause injury to thoracic structures, including the aorta, a mainstem bronchus, and the lungs. Clinicians should perform diagnostic imaging if there is the slightest concern about occult injury.",
"   </p>",
"   <p>",
"    A careful primary and secondary trauma survey should be performed looking for other injuries. Consider concomitant injuries as a source of patient distress. Perform a careful neurologic examination looking for gross deficits and less obvious signs of cranial or peripheral nerve injury. General assessment of the trauma patient is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Airway management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct injury to the airway or the neck may require immediate airway protection. Airway management in these patients can be difficult. A systematic approach is needed, and must address the following questions (",
"    <a class=\"graphic graphic_algorithm graphicRef75200 \" href=\"UTD.htm?23/41/24223\">",
"     algorithm 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Does the patient require emergent airway protection?",
"     </li>",
"     <li>",
"      What is the best approach and technique for airway protection?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with penetrating neck injury (PNI) in obvious distress (eg, respiratory distress, severe hemorrhage, extensive or sucking neck wound, shock) require immediate stabilization of the airway. Other patients with neck trauma may require airway protection based on the projected course of their disease. A general discussion of how to approach the difficult airway is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=see_link\">",
"     \"The difficult airway in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Signs that strongly suggest the need to secure the airway emergently include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Significant bleeding or hematoma",
"     </li>",
"     <li>",
"      Hemoptysis",
"     </li>",
"     <li>",
"      Subcutaneous emphysema",
"     </li>",
"     <li>",
"      Bruit or thrill",
"     </li>",
"     <li>",
"      Neurologic deficit",
"     </li>",
"     <li>",
"      Distorted neck anatomy",
"     </li>",
"     <li>",
"      Stridor",
"     </li>",
"     <li>",
"      Difficulty or pain when swallowing secretions",
"     </li>",
"     <li>",
"      Abnormal voice, especially hoarseness (\"hot potato voice\")",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the airway is felt to be threatened but anatomic structures and relationships are preserved, rapid sequence intubation (RSI) is appropriate to establish an airway [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/19,34,35\">",
"     19,34,35",
"    </a>",
"    ]. One retrospective review of airway management in patients with PNI performed at a major urban trauma center found RSI to be a safe and effective approach [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/35\">",
"     35",
"    </a>",
"    ]. Other centers have found similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/36\">",
"     36",
"    </a>",
"    ]. In-line stabilization of the cervical spine by an assistant is indicated if spinal injury is suspected, although spine injuries are uncommon with PNI. Rescue airway devices (eg, laryngeal mask airway) can be used if placement of an endotracheal tube is unsuccessful as long this does not delay the establishment of a needed surgical airway. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H932876\">",
"     'Cervical spine immobilization'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    RSI should not be used and a surgical airway is recommended if significant trauma or obstruction above the larynx is likely to preclude successful placement of an endotracheal tube (ETT), or if anatomy is sufficiently distorted that the normal anterior surface landmarks of the airway cannot be identified. Neuromuscular paralysis is often unnecessary when penetrating injury causes partial or complete transection and exposure of the trachea. In these cases, the caudad portion of the exposed trachea can be stabilized with a towel clip or clamp and intubated directly.",
"   </p>",
"   <p>",
"    If endotracheal intubation is deemed necessary in an initially stable patient, based upon the projected course of injury, and the airway is predicted to be difficult because of distorted anatomy, the clinician may elect to use an \"awake look\" approach via laryngoscopy. This approach entails giving the patient procedural sedation and topical anesthesia to enable direct or fiberoptic laryngoscopy and intubation, if conditions are favorable. When direct airway injury is suspected (eg, subcutaneous air is present in the soft tissues of the neck), we prefer a fiberoptic approach because it enables the clinician to determine the integrity of the interior of the airway above and below the vocal cords. The &ldquo;awake look&rdquo; approach is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=see_link&amp;anchor=H21#H21\">",
"     \"The difficult airway in adults\", section on 'Awake technique'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend simultaneous preparation for RSI and a surgical airway (ie, double set-up) if an \"awake look\" approach is used. Some clinicians suggest avoiding an \"awake look\" approach because of concerns that it can precipitate airway collapse. However, this assertion is unproven.",
"   </p>",
"   <p>",
"    The best method to achieve definitive airway control in the setting of PNI may vary according to clinical circumstances, clinician skill, and hospital resources [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/37\">",
"     37",
"    </a>",
"    ]. Nevertheless, the following concepts generally apply:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoid techniques not performed under direct or fiberoptic visualization. Blind placement of an ETT into a lacerated tracheal segment can create a false lumen outside the trachea or convert a partial tracheal laceration into a complete transection.",
"     </li>",
"     <li>",
"      Be prepared for unexpected difficulty. Have available and ready for use two suction devices, a range of different sized ETTs, rescue airway devices, and a surgical airway kit. We recommend a double set-up for patients with PNI in whom orotracheal intubation is attempted. Patients with neck trauma can deteriorate quickly and may have abnormalities that complicate ETT placement but are not apparent externally.",
"     </li>",
"     <li>",
"      Bag mask ventilation (BMV) to preoxygenate in preparation for RSI or to reoxygenate following a failed attempt at intubation may force air into injured tissue planes and distort airway anatomy. Although it is appropriate to perform BMV to oxygenate patients when necessary, ventilation should be done as gently as necessary, and with vigilance to ensure it is not creating more harm than benefit.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Invasive airway management (eg, cricothyroidotomy) represents the standard approach when orotracheal intubation, by any method, is unsuccessful or contraindicated. Indications for a surgical airway include massive upper airway distortion, massive midface trauma, and inability to visualize the glottis because of heavy bleeding, edema, or anatomic disruption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=see_link\">",
"     \"Emergent surgical cricothyrotomy (cricothyroidotomy)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cricothyroidotomy can be difficult in a patient with anatomical distortion. The procedure is relatively contraindicated if an anterior neck hematoma exists or a laryngeal injury is suspected, but may be the only option in some patients with PNI. If the clinician suspects partial or complete laryngeal transection, a fiberoptic approach or a tracheostomy inferior to the injury may be necessary. Whenever possible, patients whose external landmarks are sufficiently distorted to make cricothyroidotomy difficult or impossible are intubated awake using a flexible fiberoptic intubating scope.",
"   </p>",
"   <p>",
"    Percutaneous needle transtracheal or cricothyroid jet ventilation can provide oxygen to adult and pediatric patients while arrangements are made to establish a definitive airway. Clinicians must take care to avoid catheter misplacement or dislodgement, which can force air into the tissues and distort normal airway anatomy. There is no evidence to support the use of percutaneous oxygenation in patients with PNI, and the technique is best reserved for small children in whom formal cricothyroidotomy is difficult or impossible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16441?source=see_link\">",
"     \"Needle cricothyroidotomy with percutaneous transtracheal ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not perform blind nasotracheal intubation (BNI) in these patients. BNI can exacerbate preexisting airway injury. It can also cause vomiting and aspiration, turbinate injury, elevated intracranial pressure, bleeding, and in awake patients, cervical spine motion from discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Diagnostic evaluation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with unstable penetrating neck injuries (PNI) are resuscitated with emphasis upon rapid stabilization of the airway, breathing, and circulation (ABCs) as described above. Such patients are brought to the operating suite expeditiously and diagnostic testing is performed there. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Initial evaluation and interventions'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H13\">",
"     'Airway management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Stable patients with PNI must be monitored closely, as described above, while diagnostic evaluation proceeds. Clinicians must remain alert for delayed presentations of airway compromise or other injuries. Multiple studies suggest that asymptomatic patients with PNI can be managed nonoperatively. Therefore, the emergency clinician often initiates the search for injuries to the pulmonary, vascular, digestive, and neurological systems, following the initial trauma evaluation. Although careful physical examination identifies most arterial wounds, it does not detect some important injuries, particularly those to the esophagus. Venous injuries can also be missed. Clinicians should perform diagnostic imaging if there is any reasonable suspicion for occult injury. The work-up for specific injuries is discussed below.",
"   </p>",
"   <p>",
"    No consensus exists about the role of physical examination to detect surgical injuries; most trauma specialists use ancillary testing but a small minority continues to advocate mandatory surgical exploration. At remote community hospitals and nontrauma centers, mandatory surgical exploration of Zone II injuries may be performed to avoid missing an injury that would otherwise present in delayed fashion when emergent treatment could not be provided. However, even in areas with limited trauma services, a more selective approach to surgical exploration may be reasonable [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Definitive management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether physical examination can reliably detect significant visceral or vascular injuries from penetrating neck trauma remains a source of debate. Two prospective studies underscore this difference of opinion. The first evaluated 393 consecutive patients with PNI and found that 30 percent had significant injuries discovered during surgical neck exploration despite no evidence of such injury during the initial examination [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/3\">",
"     3",
"    </a>",
"    ]. In contrast, a second study of 223 patients with PNI concluded that careful examination using a written protocol that identified objective signs of injury (eg, large expanding hematomas, severe active bleeding, shock not responding to fluids, diminished radial pulse, bruit) reliably predicted major",
"    <strong>",
"     vascular",
"    </strong>",
"    trauma requiring treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of retrospective observational studies suggest physical examination may be most accurate for determining the presence of arterial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. Similar studies suggest physical examination is least accurate at detecting esophageal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/22,44,45\">",
"     22,44,45",
"    </a>",
"    ]. Venous injuries may also be difficult to detect. Additional prospective trials and follow-up studies are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Diagnostic studies overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many trauma specialists advocate computed tomography with angiography (CT-A) for the evaluation of stable patients with PNI, no consensus exists as to the best diagnostic approach, and practice varies based upon institutional resources and protocols, the most likely injuries, and local surgical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/22,46-49\">",
"     22,46-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If aerodigestive injury is suspected, CT alone or in conjunction with esophageal studies (contrast swallow and endoscopy) provides an accurate diagnosis in most cases. Esophageal injury can be difficult to diagnose and no \"gold standard\" for testing has been established. Suspicion for vascular injury prompts vascular studies which vary by institution. Options include CT-A and color-flow Doppler ultrasound (CFD). CT-A is sensitive for vascular injury and generally available [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/50\">",
"     50",
"    </a>",
"    ]. Conventional angiography may be needed if metallic debris obscures bullet trajectory and anatomic detail. CFD is increasingly used, but is operator-dependent and not always available. Studies other than CT-A are generally best performed in consultation with the trauma surgeon to ensure an appropriate and efficient work-up. As an example, some surgeons prefer bronchoscopy for Zone I injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Laryngotracheal injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some laryngotracheal (LT) injuries are obvious, while others require diagnostic imaging. Multidetector helical CT (MDCT) is the tool used most often to screen for these injuries in stable patients. MDCT provides anatomic detail about laryngeal integrity and is useful when cervical spine immobilization is necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. MDCT provides better images of mineralized cartilage than plain radiographs.",
"   </p>",
"   <p>",
"    MDCT has some limitations. Degloving injury of the cartilage with denuded mucosa can be missed, as can certain types of LT separation and mucosal perforation. Pediatric cartilaginous structures are poorly calcified and may be more difficult to visualize than an adult larynx.",
"   </p>",
"   <p>",
"    Further studies may be necessary in patients with clinical signs of injury or at high risk for occult injury whose initial imaging is nondiagnostic. Endoscopy or laryngoscopy provides alternatives for the diagnosis of LT trauma, and is preferred in some hospitals [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Endoscopy enables thorough evaluation when scatter artifact from metallic objects obscures CT images.",
"   </p>",
"   <p>",
"    Flexible nasopharyngoscopy allows visualization of the hypopharynx and supralaryngeal structures in an awake or sedated patient, while flexible laryngoscopy allows evaluation of more distal structures. Rigid endoscopy allows for evaluation of the distal airway, but requires general anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Vascular injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some controversy remains about the best way to assess for vascular injury in stable patients with PNI. The preferred diagnostic study varies by hospital and selection should be made in consultation with the trauma surgeon.",
"   </p>",
"   <p>",
"    In most trauma centers, multidetector helical CT scan with angiography (CT-A) has replaced conventional angiography for the evaluation of vascular injury in PNI [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/46,55\">",
"     46,55",
"    </a>",
"    ]. The sensitivity and specificity of CT-A for detecting significant vascular wounds in the neck approaches that of standard angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/46,56,57\">",
"     46,56,57",
"    </a>",
"    ]. Other benefits of CT-A include wide availability, detection of nonvascular injuries, and speed. The entire neck can be scanned in under five minutes, and the head and chest can also be studied when necessary.",
"   </p>",
"   <p>",
"    Angiography demonstrates sensitivity and specificity of close to 100 percent and has been considered the gold standard in stable patients for decades [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/6\">",
"     6",
"    </a>",
"    ]. It may be the best study to diagnose certain vascular injuries, especially if procedures such as embolization or stent placement are anticipated or when artifacts obscure CT images of the vasculature. Suspected distal carotid artery lesions may be better assessed using angiography as less invasive studies have limitations in that region. Some have argued that arteriography enables better surgical planning but this concept is largely obsolete [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/6,56,58,59\">",
"     6,56,58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two or four vessel angiography is costly, invasive (complications occur in approximately 2 percent of patients), and consumes a great deal of resources. These factors combined with the high number of negative studies have led many trauma specialists to use noninvasive tests coupled with careful physical examination for the initial evaluation of possible vascular neck injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/7,60,61\">",
"     7,60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If chosen, angiography should include the carotid and vertebral vessels, the intracranial portion of the carotid artery in zone III injuries, and the aortic arch with its branches in zone I injuries.",
"   </p>",
"   <p>",
"    Color flow Doppler ultrasound (CFD) in combination with a careful physical examination can detect or suggest the presence of vascular injury and may represent an alternative to angiography in select patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/58,62,63\">",
"     58,62,63",
"    </a>",
"    ]. According to one prospective study, CFD and careful physical examination are 100 percent sensitive and specific compared with conventional angiography at detecting vascular injury that requires surgical repair [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/64\">",
"     64",
"    </a>",
"    ]. CFD is fast, noninvasive, and inexpensive.",
"   </p>",
"   <p>",
"    CFD has limitations, including an inability to image the distal intracranial portions of the carotid artery and portions of the vertebral artery and the proximal subclavian vessels. In addition, CFD may not accurately detect pseudoaneurysms and artifact (eg, from bony fractures, metallic foreign bodies, subcutaneous air) can obscure vascular structures. The quality of CFD studies depends upon operator skill.",
"   </p>",
"   <p>",
"    MR angiogram is not a first-line study to detect vascular injury following penetrating neck trauma. There are no large, prospective studies comparing MRI to angiography. MRI has several drawbacks, including lack of availability and inaccessibility. Monitoring of the patient is difficult during the performance of an MRI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Pharyngoesophageal injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;More trauma centers are using a selective approach to surgical exploration in patients with penetrating neck injury (PNI). This can delay the detection of esophageal injury and such delays can increase mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/26\">",
"     26",
"    </a>",
"    ]. Furthermore, debate persists about whether esophageal injuries requiring surgery manifest obvious clinical findings [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/26,65\">",
"     26,65",
"    </a>",
"    ]. Given the potential difficulties in diagnosis and the consequence of delays, many trauma specialists obtain imaging studies to rule out esophageal injury in all cases of nonsuperficial PNI. A multidetector helical CT scan (MDCT) is often the first study obtained because it can detect laryngotracheal, vascular, and esophageal injuries simultaneously and rapidly.",
"   </p>",
"   <p>",
"    A plain neck or chest radiograph showing retropharyngeal air or pneumomediastinum, respectively, suggests esophageal injury, but neither test is specific [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/66\">",
"     66",
"    </a>",
"    ]. In such cases, immediate surgical consultation is obtained to determine management and the choice of further imaging, should the patient not proceed immediately to the operating suite.",
"   </p>",
"   <p>",
"    MDCT imaging is often obtained in a patient with a zone I injury or soft signs of esophageal injury (eg, dysphagia). Evidence of a wound in close proximity to the esophagus or a nondiagnostic study in a patient with soft signs of injury necessitates immediate surgical consultation to determine further testing, which may include esophagography or endoscopy. Others may opt for surgical exploration.",
"   </p>",
"   <p>",
"    MDCT is used increasingly to assess patients with PNI. One prospective observational study found MDCT to have high sensitivity and specificity for aerodigestive injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/67\">",
"     67",
"    </a>",
"    ]. Another prospective study suggests that MDCT may lack sensitivity for detecting esophageal injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/45\">",
"     45",
"    </a>",
"    ]. Additional trials are needed to determine the test's accuracy.",
"   </p>",
"   <p>",
"    Practice guidelines from the Eastern Association for the Surgery of Trauma (EAST) suggest that either endoscopy of the esophagus or esophagography can be used to rule out significant esophageal injury in patients with PNI [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/22\">",
"     22",
"    </a>",
"    ]. However, studies of these techniques in this patient population are small and both approaches have limitations. Flexible endoscopy does not require general anesthesia, but can miss proximal esophageal injuries if views are inadequate. However, according to one small retrospective study, flexible endoscopy demonstrates high sensitivity for penetrating esophageal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/68\">",
"     68",
"    </a>",
"    ]. Rigid endoscopy exposes awake patients to the risks of general anesthesia and may be complicated by perforation. Scatter artifact from metallic objects may obscure CT images. In such cases, either form of endoscopy is preferred.",
"   </p>",
"   <p>",
"    The sensitivity of simple contrast studies (ie, esophagography) for esophageal injury is approximately 80 to 89 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/4,25\">",
"     4,25",
"    </a>",
"    ]. These studies require patient cooperation to obtain adequate views. Some believe esophagography is an adequate screening tool if clinical suspicion for esophageal injury is low [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/5,69\">",
"     5,69",
"    </a>",
"    ]. One study found the combination of esophagography and flexible endoscopy to be 100 percent sensitive for detecting esophageal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DEFINITIVE MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Consultation and disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PNI can be categorized as unstable with signs reflecting severe injury (eg, stroke, airway obstruction, shock), stable with soft signs or symptoms suggesting injury (eg, dysphagia, nonexpanding hematoma, minor bleeding), or asymptomatic.",
"   </p>",
"   <p>",
"    Unstable patients and those with hard signs of significant injury are taken emergently to the operating room for definitive treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/22\">",
"     22",
"    </a>",
"    ]. Asymptomatic patients can generally be observed and evaluated with serial physical examinations or institution-specific protocols involving ancillary studies. We generally obtain immediate surgical consultation for all cases of nonsuperficial penetrating neck injury (PNI) and place the asymptomatic patient in a monitored setting with close observation.",
"   </p>",
"   <p>",
"    Controversy arises with the management of stable PNI patients manifesting soft signs of injury. Computed tomography with angiography (CT-A) is a powerful tool and the initial study of choice for most of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/48\">",
"     48",
"    </a>",
"    ]. Additional testing can be based upon CT-A findings. As an example, a high (zone III) vascular lesion evident on CT-A may mandate conventional angiography and stent placement. If the CT-A is indeterminate for aerodigestive tract injury (eg, CT reading is: &ldquo;air bubbles seen; cannot exclude aerodigestive injury&rdquo;), further evaluation (eg, esophagography, endoscopy) is indicated.",
"   </p>",
"   <p>",
"    Management varies according to clinical circumstance, local surgical practice, and hospital resources. We recommend transfer to a trauma center for any patient at risk for significant injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Mandatory versus selective surgical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of PNI, particularly in stable patients, remains a source of debate among trauma surgeons. The primary controversy is whether all such patients require surgical exploration, especially for zone II injuries, or whether selected patients can be managed nonoperatively. Most research and many trauma surgeons favor some form of selective management. One early review concluded that zone II injuries have similar outcomes regardless of whether they undergo mandatory surgery or selective management, while subsequent research supports a selective approach [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/4,10,33,67\">",
"     4,10,33,67",
"    </a>",
"    ]. Practice guidelines from the Eastern Association for the Surgery of Trauma (EAST) state that both approaches are justifiable and safe [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No consensus exists about the role of physical examination to detect surgical injuries; most trauma specialists use ancillary testing but some continue to advocate mandatory surgical exploration [",
"    <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/60,70-74\">",
"     60,70-74",
"    </a>",
"    ]. At community hospitals and nontrauma centers, close serial examinations are not always possible and mandatory surgical exploration may be necessary to avoid missing an injury that would otherwise present in delayed fashion, when emergent treatment could not be provided.",
"   </p>",
"   <p>",
"    Advocates for mandatory surgery with zone II injuries believe the relative ease of access to this region makes injuries more amenable to surgical repair and thus, regardless of hemodynamic stability or signs of injury, all patients should be managed in the operating room. The proponents of a selective approach believe the multitude of diagnostic options, ranging from angiography and esophagoscopy to serial examinations without ancillary studies, allows for safe nonoperative management while avoiding unnecessary procedures.",
"   </p>",
"   <p>",
"    Debate continues about the best approach (mandatory versus selective surgery) for injuries in zones I and III. However, the selective approach has gained popularity over the past decade.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Specific injuries",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Laryngotracheal injury",
"      </strong>",
"      &ndash; A large proportion of patients with traumatic airway injuries require definitive airways [",
"      <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/75,76\">",
"       75,76",
"      </a>",
"      ]. Endotracheal intubation using rapid sequence intubation (RSI) is safe in the majority of patients, although exceptions exist [",
"      <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/35\">",
"       35",
"      </a>",
"      ]. Airway management is discussed in detail above. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Airway management'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Timely repair of certain laryngotracheal injuries is important to prevent long-term complications such as chronic pain, stenosis, or voice change.",
"     </li>",
"     <li>",
"      <strong>",
"       Pharyngoesophageal injuries",
"      </strong>",
"      &ndash; Obtain surgical consultation for all suspected pharyngoesophageal injury (PEI). Most PEIs are treated surgically, but select patients may be managed nonoperatively [",
"      <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/5\">",
"       5",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      If not promptly diagnosed, PEI can cause mediastinitis and abscess or empyema formation from the leakage of gastric contents. Clinicians should begin treatment with broad-spectrum antibiotics in all patients with possible PEI. Although some trauma specialists advocate decompressing the stomach with a nasogastric tube, performing a blind procedure in a patient with PEI entails significant risk [",
"      <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/2\">",
"       2",
"      </a>",
"      ]. We do not believe this procedure should be performed blindly in the emergency department.",
"     </li>",
"     <li>",
"      <strong>",
"       Vascular injuries",
"      </strong>",
"      &ndash; Obtain immediate consultation with a vascular surgeon if vascular injury from a PNI is suspected. A trauma or thoracic surgeon may be needed and should be consulted if a zone I vascular injury is suspected.",
"      <br/>",
"      <br/>",
"      A range of surgical and interventional options exist for the management of vascular injury, including embolization, ligation, stent placement, surgical repair, and revascularization. Early revascularization offers the best chance for successful outcome when managing injuries to the carotid artery [",
"      <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/2,6,77,78\">",
"       2,6,77,78",
"      </a>",
"      ]. Coma portends a poor outcome. Inability initially to differentiate coma due to neurologic insult from coma due to drug or alcohol abuse can confuse the clinical picture and management options.",
"     </li>",
"     <li>",
"      <strong>",
"       Neurological injuries",
"      </strong>",
"      &ndash; Cervical spine injury is uncommon following penetrating trauma to the neck. A retrospective review of a large trauma database found the incidence of cervical spine fracture to be 1.35 percent with gunshot wounds and 0.12 percent with stab wounds to the neck. The incidence of spinal cord injury was even lower. All patients with cervical spinal cord injury had a neurologic deficit at initial presentation. MDCT and possibly MRI are useful for the diagnosis of these injuries [",
"      <a class=\"abstract\" href=\"UTD.htm?1/62/2026/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Pitfalls and pearls",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Concentrate on imminent and delayed signs of airway compromise. Do not allow dramatic thoracic injuries to distract from essential airway management.",
"     </li>",
"     <li>",
"      Be prepared to provide a surgical airway immediately if attempts at oral intubation fail. Use a double set-up.",
"     </li>",
"     <li>",
"      Wounds to the distal carotid artery can cause neurological deficits that mimic stroke, spinal cord, or head injury.",
"     </li>",
"     <li>",
"      Zone I injuries can involve life-threatening thoracic injuries.",
"     </li>",
"     <li>",
"      Maintain high concern for occult esophageal injuries, which can cause life-threatening sequela.",
"     </li>",
"     <li>",
"      Never delay surgical consultation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mortality in patients with penetrating neck injury (PNI) appears to be highest with zone I injuries (below the cricoid cartilage) (",
"      <a class=\"graphic graphic_figure graphicRef52642 \" href=\"UTD.htm?13/45/14034\">",
"       figure 1",
"      </a>",
"      ). Clinical neck anatomy is described above. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any patient with a PNI can decompensate rapidly and should be transported immediately to the nearest trauma center if possible. Standard prehospital trauma care is provided. Impaled objects should",
"      <strong>",
"       NOT",
"      </strong>",
"      be removed in the field. Bag mask ventilation (BMV) can become problematic if an airway injury is present and air is forced into soft tissue planes leading to anatomical distortion. Cervical spine injury from PNI is uncommon and immobilization is not necessary in many instances. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Prehospital care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with PNI in obvious distress (eg, respiratory distress, severe hemorrhage, extensive or sucking neck wound, shock) require immediate stabilization of the airway. Initially stable PNI patients may require airway protection based on the projected course of their disease. Signs that strongly suggest the need to secure the airway emergently include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Significant bleeding or hematoma",
"     </li>",
"     <li>",
"      Hemoptysis",
"     </li>",
"     <li>",
"      Subcutaneous emphysema",
"     </li>",
"     <li>",
"      Bruit or thrill",
"     </li>",
"     <li>",
"      Neurologic deficit",
"     </li>",
"     <li>",
"      Distorted neck anatomy",
"     </li>",
"     <li>",
"      Stridor",
"     </li>",
"     <li>",
"      Difficulty or pain when swallowing secretions",
"     </li>",
"     <li>",
"      Abnormal voice, especially hoarseness (\"hot potato voice\") (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Airway management'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In most cases of PNI, rapid sequence intubation (RSI) can be used to establish an airway when necessary. Intubation should be performed under direct laryngoscopic or fiberoptic visualization. Be ready for unexpected difficulty; prepare simultaneously for orotracheal and surgical airway management (ie, double set-up). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Airway management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial management of patients with PNI follows standard trauma protocols. Special considerations in PNI include the following: Zone I neck injuries can involve intrathoracic structures. Traumatic arrest in the emergency department (ED) is an indication for emergency thoracotomy if feasible in patients with PNI. Do",
"      <strong>",
"       NOT",
"      </strong>",
"      explore neck wounds in the ED. Obtain emergency surgical consultation for all PNIs, aside from obviously superficial injuries. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Initial evaluation and interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Unstable patients with PNI receive definitive care in the operating suite. Stable patients often require additional imaging studies and observation in a monitored setting. Stable patients at nontrauma centers with concerning symptoms or signs should be transferred to a trauma center if definitive care cannot be provided.",
"     </li>",
"     <li>",
"      Careful physical examination identifies most arterial wounds, but can miss important esophageal and venous injuries. In general, additional evaluation (eg, CT, esophagoscopy) is necessary for any PNI that violates the platysmas.",
"     </li>",
"     <li>",
"      Laryngotracheal injuries can result in respiratory distress, stridor, subcutaneous air, hemoptysis, odynophagia, dysphonia, or anterior neck tenderness. Signs of vascular injury include significant bleeding or hematoma, decreased or absent peripheral pulses, global or focal neurologic deficits (eg, stroke), and bruits or thrills. Intact pulses do",
"      <strong>",
"       NOT",
"      </strong>",
"      rule out vascular injury. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Laryngotracheal injuries'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Vascular injuries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pharyngoesophageal injuries are uncommon and often occult but are associated with high morbidity and mortality. Clinicians should aggressively search for pharyngoesophageal injuries in patients with any suggestive signs. These may include dysphagia, blood in the saliva, hematemesis, and subcutaneous air. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pharyngoesophageal injuries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Penetrating neck injury can involve the central nervous system (spinal cord) or the peripheral nervous system (cranial nerves including VII though XII, sympathetic chain, peripheral nerve roots, brachial plexus). Specific injuries are described in the text. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Nervous system injuries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although many trauma specialists advocate computed tomography with angiography (CT-A) for the evaluation of stable patients with PNI, no consensus exists as to the best diagnostic approach, and practice varies based upon institutional resources and protocols, the most likely injuries, and local surgical practice. The relative advantages and disadvantages of available tests for specific injuries are discussed in the text. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Emergency management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most research supports selective operative management of stable patients with PNI. Controversy surrounds the indications for mandatory surgical exploration, particularly with zone II injuries. Definitive management of stable patients with PNI varies by institution and local surgical practice. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Mandatory versus selective surgical management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2870029\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/1\">",
"      Thal ER, Meyer DM. Penetrating neck trauma. Curr Probl Surg 1992; 29:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/2\">",
"      McConnell DB, Trunkey DD. Management of penetrating trauma to the neck. Adv Surg 1994; 27:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/3\">",
"      Apffelstaedt JP, M&uuml;ller R. Results of mandatory exploration for penetrating neck trauma. World J Surg 1994; 18:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/4\">",
"      Asensio JA, Valenziano CP, Falcone RE, Grosh JD. Management of penetrating neck injuries. The controversy surrounding zone II injuries. Surg Clin North Am 1991; 71:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/5\">",
"      Bryant AS, Cerfolio RJ. Esophageal trauma. Thorac Surg Clin 2007; 17:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/6\">",
"      Demetriades D, Skalkides J, Sofianos C, et al. Carotid artery injuries: experience with 124 cases. J Trauma 1989; 29:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/7\">",
"      Demetriades D, Theodorou D, Cornwell E, et al. Evaluation of penetrating injuries of the neck: prospective study of 223 patients. World J Surg 1997; 21:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/8\">",
"      Demetriades D, Theodorou D, Cornwell E, et al. Transcervical gunshot injuries: mandatory operation is not necessary. J Trauma 1996; 40:758.",
"     </a>",
"    </li>",
"    <li>",
"     Dennis JW. Carotid and vertebral artery injuries. In: Vascular Surgery: Theory and Practice, Callow AD, Calvin BE.  (Eds), Appleton and Lange, Norwalk 1993. p.1039.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/10\">",
"      Bell RB, Osborn T, Dierks EJ, et al. Management of penetrating neck injuries: a new paradigm for civilian trauma. J Oral Maxillofac Surg 2007; 65:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/11\">",
"      Demetriades D, Asensio JA, Velmahos G, Thal E. Complex problems in penetrating neck trauma. Surg Clin North Am 1996; 76:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/12\">",
"      Mittal VK, Paulson TJ, Colaiuta E, et al. Carotid artery injuries and their management. J Cardiovasc Surg (Torino) 2000; 41:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/13\">",
"      Asensio JA, Berne J, Demetriades D, et al. Penetrating esophageal injuries: time interval of safety for preoperative evaluation--how long is safe? J Trauma 1997; 43:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/14\">",
"      Lustenberger T, Talving P, Lam L, et al. Unstable cervical spine fracture after penetrating neck injury: a rare entity in an analysis of 1,069 patients. J Trauma 2011; 70:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/15\">",
"      Monson DO, Saletta JD, Freeark RJ. Carotid vertebral trauma. J Trauma 1969; 9:987.",
"     </a>",
"    </li>",
"    <li>",
"     Hollingstead WH, Rosse C. Textbook of Anatomy, 4th, Lippincott, Williams, &amp; Wilkins, Philadelphia 1985. p.823.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/17\">",
"      Bond SJ, Schnier GC, Miller FB. Air-powered guns: too much firepower to be a toy. J Trauma 1996; 41:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/18\">",
"      Rhee P, Kuncir EJ, Johnson L, et al. Cervical spine injury is highly dependent on the mechanism of injury following blunt and penetrating assault. J Trauma 2006; 61:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/19\">",
"      Brywczynski JJ, Barrett TW, Lyon JA, Cotton BA. Management of penetrating neck injury in the emergency department: a structured literature review. Emerg Med J 2008; 25:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/20\">",
"      Vanderlan WB, Tew BE, Seguin CY, et al. Neurologic sequelae of penetrating cervical trauma. Spine (Phila Pa 1976) 2009; 34:2646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/21\">",
"      Inaba K, Barmparas G, Ibrahim D, et al. Clinical examination is highly sensitive for detecting clinically significant spinal injuries after gunshot wounds. J Trauma 2011; 71:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/22\">",
"      Tisherman SA, Bokhari F, Collier B, et al. Clinical practice guideline: penetrating zone II neck trauma. J Trauma 2008; 64:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/23\">",
"      Stuke LE, Pons PT, Guy JS, et al. Prehospital spine immobilization for penetrating trauma--review and recommendations from the Prehospital Trauma Life Support Executive Committee. J Trauma 2011; 71:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/24\">",
"      Demetriades D, Charalambides D, Lakhoo M. Physical examination and selective conservative management in patients with penetrating injuries of the neck. Br J Surg 1993; 80:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/25\">",
"      Weigelt JA, Thal ER, Snyder WH 3rd, et al. Diagnosis of penetrating cervical esophageal injuries. Am J Surg 1987; 154:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/26\">",
"      Asensio JA, Chahwan S, Forno W, et al. Penetrating esophageal injuries: multicenter study of the American Association for the Surgery of Trauma. J Trauma 2001; 50:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/27\">",
"      Bent JP 3rd, Silver JR, Porubsky ES. Acute laryngeal trauma: a review of 77 patients. Otolaryngol Head Neck Surg 1993; 109:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/28\">",
"      Minard G, Kudsk KA, Croce MA, et al. Laryngotracheal trauma. Am Surg 1992; 58:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/29\">",
"      Eggen JT, Jorden RC. Airway management, penetrating neck trauma. J Emerg Med 1993; 11:381.",
"     </a>",
"    </li>",
"    <li>",
"     Murphy MF, Zane RD. Distorted airways and acute upper airway obstruction. In: Manual of Emergency Airway Management, 3rd, Walls RM, Murphy MF.  (Eds), Lippincott Willaims &amp; Wilkins, Philadelphia 2008. p.332.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/31\">",
"      Navsaria P, Thoma M, Nicol A. Foley catheter balloon tamponade for life-threatening hemorrhage in penetrating neck trauma. World J Surg 2006; 30:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/32\">",
"      Gilroy D, Lakhoo M, Charalambides D, Demetriades D. Control of life-threatening haemorrhage from the neck: a new indication for balloon tamponade. Injury 1992; 23:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/33\">",
"      Van Waes OJ, Cheriex KC, Navsaria PH, et al. Management of penetrating neck injuries. Br J Surg 2012; 99 Suppl 1:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/34\">",
"      Walls RM. Airway management. Emerg Med Clin North Am 1993; 11:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/35\">",
"      Mandavia DP, Qualls S, Rokos I. Emergency airway management in penetrating neck injury. Ann Emerg Med 2000; 35:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/36\">",
"      Shearer VE, Giesecke AH. Airway management for patients with penetrating neck trauma: a retrospective study. Anesth Analg 1993; 77:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/37\">",
"      Tallon JM, Ahmed JM, Sealy B. Airway management in penetrating neck trauma at a Canadian tertiary trauma centre. CJEM 2007; 9:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/38\">",
"      Ligier B, Buchman TG, Breslow MJ, Deutschman CS. The role of anesthetic induction agents and neuromuscular blockade in the endotracheal intubation of trauma victims. Surg Gynecol Obstet 1991; 173:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/39\">",
"      Hussain Zaidi SM, Ahmad R. Penetrating neck trauma: a case for conservative approach. Am J Otolaryngol 2011; 32:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/40\">",
"      Azuaje RE, Jacobson LE, Glover J, et al. Reliability of physical examination as a predictor of vascular injury after penetrating neck trauma. Am Surg 2003; 69:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/41\">",
"      Sekharan J, Dennis JW, Veldenz HC, et al. Continued experience with physical examination alone for evaluation and management of penetrating zone 2 neck injuries: results of 145 cases. J Vasc Surg 2000; 32:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/42\">",
"      Eddy VA. Is routine arteriography mandatory for penetrating injury to zone 1 of the neck? Zone 1 Penetrating Neck Injury Study Group. J Trauma 2000; 48:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/43\">",
"      Ferguson E, Dennis JW, Vu JH, Frykberg ER. Redefining the role of arterial imaging in the management of penetrating zone 3 neck injuries. Vascular 2005; 13:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/44\">",
"      Bishara RA, Pasch AR, Douglas DD, et al. The necessity of mandatory exploration of penetrating zone II neck injuries. Surgery 1986; 100:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/45\">",
"      Gonzalez RP, Falimirski M, Holevar MR, Turk B. Penetrating zone II neck injury: does dynamic computed tomographic scan contribute to the diagnostic sensitivity of physical examination for surgically significant injury? A prospective blinded study. J Trauma 2003; 54:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/46\">",
"      Woo K, Magner DP, Wilson MT, Margulies DR. CT angiography in penetrating neck trauma reduces the need for operative neck exploration. Am Surg 2005; 71:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/47\">",
"      Gracias VH, Reilly PM, Philpott J, et al. Computed tomography in the evaluation of penetrating neck trauma: a preliminary study. Arch Surg 2001; 136:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/48\">",
"      Munera F, Danton G, Rivas LA, et al. Multidetector row computed tomography in the management of penetrating neck injuries. Semin Ultrasound CT MR 2009; 30:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/49\">",
"      Inaba K, Branco BC, Menaker J, et al. Evaluation of multidetector computed tomography for penetrating neck injury: a prospective multicenter study. J Trauma Acute Care Surg 2012; 72:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/50\">",
"      Schroeder JW, Baskaran V, Aygun N. Imaging of traumatic arterial injuries in the neck with an emphasis on CTA. Emerg Radiol 2010; 17:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/51\">",
"      Fuhrman GM, Stieg FH 3rd, Buerk CA. Blunt laryngeal trauma: classification and management protocol. J Trauma 1990; 30:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/52\">",
"      Francis S, Gaspard DJ, Rogers N, Stain SC. Diagnosis and management of laryngotracheal trauma. J Natl Med Assoc 2002; 94:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/53\">",
"      O'Mara W, Hebert AF. External laryngeal trauma. J La State Med Soc 2000; 152:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/54\">",
"      Jacobs I, Niknejad G, Kelly K, et al. Hypopharyngeal perforation after blunt neck trauma: case report and review of the literature. J Trauma 1999; 46:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/55\">",
"      Stuhlfaut JW, Barest G, Sakai O, et al. Impact of MDCT angiography on the use of catheter angiography for the assessment of cervical arterial injury after blunt or penetrating trauma. AJR Am J Roentgenol 2005; 185:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/56\">",
"      M&uacute;nera F, Soto JA, Palacio D, et al. Diagnosis of arterial injuries caused by penetrating trauma to the neck: comparison of helical CT angiography and conventional angiography. Radiology 2000; 216:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/57\">",
"      M&uacute;nera F, Soto JA, Palacio DM, et al. Penetrating neck injuries: helical CT angiography for initial evaluation. Radiology 2002; 224:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/58\">",
"      Fry WR, Dort JA, Smith RS, et al. Duplex scanning replaces arteriography and operative exploration in the diagnosis of potential cervical vascular injury. Am J Surg 1994; 168:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/59\">",
"      M&uacute;nera F, Cohn S, Rivas LA. Penetrating injuries of the neck: use of helical computed tomographic angiography. J Trauma 2005; 58:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/60\">",
"      Rivers SP, Patel Y, Delany HM, Veith FJ. Limited role of arteriography in penetrating neck trauma. J Vasc Surg 1988; 8:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/61\">",
"      Jarvik JG, Philips GR 3rd, Schwab CW, et al. Penetrating neck trauma: sensitivity of clinical examination and cost-effectiveness of angiography. AJNR Am J Neuroradiol 1995; 16:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/62\">",
"      Ginzburg E, Montalvo B, LeBlang S, et al. The use of duplex ultrasonography in penetrating neck trauma. Arch Surg 1996; 131:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/63\">",
"      Corr P, Abdool Carrim AT, Robbs J. Colour-flow ultrasound in the detection of penetrating vascular injuries of the neck. S Afr Med J 1999; 89:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/64\">",
"      Demetriades D, Theodorou D, Cornwell E 3rd, et al. Penetrating injuries of the neck in patients in stable condition. Physical examination, angiography, or color flow Doppler imaging. Arch Surg 1995; 130:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/65\">",
"      Vassiliu P, Baker J, Henderson S, et al. Aerodigestive injuries of the neck. Am Surg 2001; 67:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/66\">",
"      Biffl WL, Moore EE, Rehse DH, et al. Selective management of penetrating neck trauma based on cervical level of injury. Am J Surg 1997; 174:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/67\">",
"      Inaba K, Munera F, McKenney M, et al. Prospective evaluation of screening multislice helical computed tomographic angiography in the initial evaluation of penetrating neck injuries. J Trauma 2006; 61:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/68\">",
"      Flowers JL, Graham SM, Ugarte MA, et al. Flexible endoscopy for the diagnosis of esophageal trauma. J Trauma 1996; 40:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/69\">",
"      Klyachkin ML, Rohmiller M, Charash WE, et al. Penetrating injuries of the neck: selective management evolving. Am Surg 1997; 63:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/70\">",
"      Rose SC, Moore EE. Trauma angiography: the use of clinical findings to improve patient selection and case preparation. J Trauma 1988; 28:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/71\">",
"      Velmahos GC, Souter I, Degiannis E, et al. Selective surgical management in penetrating neck injuries. Can J Surg 1994; 37:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/72\">",
"      Sclafani SJ, Cavaliere G, Atweh N, et al. The role of angiography in penetrating neck trauma. J Trauma 1991; 31:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/73\">",
"      Walsh MS. The management of penetrating injuries of the anterior triangle of the neck. Injury 1994; 25:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/74\">",
"      Siegrist B, Steeb G. Penetrating neck injuries. South Med J 2000; 93:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/75\">",
"      Kummer C, Netto FS, Rizoli S, Yee D. A review of traumatic airway injuries: potential implications for airway assessment and management. Injury 2007; 38:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/76\">",
"      Grewal H, Rao PM, Mukerji S, Ivatury RR. Management of penetrating laryngotracheal injuries. Head Neck 1995; 17:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/77\">",
"      Feliciano, DV. A new look at penetrating carotid artery injuries. Adv Trauma Crit Care 1994; 9:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/62/2026/abstract/78\">",
"      Ledgerwood AM, Mullins RJ, Lucas CE. Primary repair vs ligation for carotid artery injuries. Arch Surg 1980; 115:488.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 355 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-094BD8D684-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_62_2026=[""].join("\n");
var outline_f1_62_2026=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MECHANISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREHOSPITAL CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H932869\">",
"      General management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H932876\">",
"      Cervical spine immobilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Laryngotracheal injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Vascular injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pharyngoesophageal injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Nervous system injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EMERGENCY MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Initial evaluation and interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Airway management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - General approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Diagnostic studies overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Laryngotracheal injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Vascular injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Pharyngoesophageal injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DEFINITIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Consultation and disposition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Mandatory versus selective surgical management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Specific injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Pitfalls and pearls",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2870029\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/355\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/355|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?11/21/11615\" title=\"algorithm 1\">",
"      Penetrating neck injury through platysma algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?23/41/24223\" title=\"algorithm 2\">",
"      Traumatized airway management algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/355|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/45/14034\" title=\"figure 1\">",
"      Neck zones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/25/42388\" title=\"figure 2\">",
"      Compartments of neck",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=related_link\">",
"      Emergent surgical cricothyrotomy (cricothyroidotomy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=related_link\">",
"      Initial evaluation and management of shock in adult trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=related_link\">",
"      Initial management of trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16441?source=related_link\">",
"      Needle cricothyroidotomy with percutaneous transtracheal ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17482?source=related_link\">",
"      Prehospital care of the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=related_link\">",
"      The difficult airway in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_62_2027="Egg substitutes";
var content_f1_62_2027=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F62743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F62743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Substitutions for egg in recipes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       2 Tablespoons of fruit puree (binding only)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1 Tablespoon of ground flax seeds, 3 Tablespoons water (binding only)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1&frac12; Tablespoons water, 1&frac12; Tablespoons oil, 1 teaspoon baking powder (leavening and binding)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1 teaspoon baking powder, 1 Tablespoon liquid, 1 Tablespoon vinegar (leavening and binding)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Potato based commercial egg substitute  from Ener-G foods (leavening and binding)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1 packet of gelatin, 2 Tablespoons warm water - mix when ready to use (leavening and binding)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1 teaspoon yeast dissolved in &frac14; cup warm water (leavening and binding)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_62_2027=[""].join("\n");
var outline_f1_62_2027=null;
var title_f1_62_2028="Insulin pharmacokinetics";
var content_f1_62_2028=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F73676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F73676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pharmacokinetics of the most commonly used insulin preparations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Insulin type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Onset of action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Peak effect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration of action",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lispro, aspart, glulisine",
"       </td>",
"       <td>",
"        5 to 15 minutes",
"       </td>",
"       <td>",
"        45 to 75 minutes",
"       </td>",
"       <td>",
"        Two&nbsp;to&nbsp;four hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Regular",
"       </td>",
"       <td>",
"        About 30 minutes",
"       </td>",
"       <td>",
"        Two to four&nbsp;hours",
"       </td>",
"       <td>",
"        Five&nbsp;to&nbsp;eight hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NPH",
"       </td>",
"       <td>",
"        About&nbsp;two hours",
"       </td>",
"       <td>",
"        4 to 12 hours",
"       </td>",
"       <td>",
"        18 to 28 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insulin glargine",
"       </td>",
"       <td>",
"        About&nbsp;two hours",
"       </td>",
"       <td>",
"        No peak",
"       </td>",
"       <td>",
"        20 to &gt;24 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insulin detemir",
"       </td>",
"       <td>",
"        About&nbsp;two hours",
"       </td>",
"       <td>",
"        Three&nbsp;to&nbsp;nine hours",
"       </td>",
"       <td>",
"        6 to 24 hours*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NPL",
"       </td>",
"       <td>",
"        About&nbsp;two hours",
"       </td>",
"       <td>",
"        Six&nbsp;hours",
"       </td>",
"       <td>",
"        15 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insulin degludec",
"       </td>",
"       <td>",
"        About two hours",
"       </td>",
"       <td>",
"        No peak",
"       </td>",
"       <td>",
"        &gt;40 hours",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NPH: neutral protamine hagedorn; NPL: neutral protamine lispro.",
"     <br>",
"      * Duration of action is dose-dependent. At higher doses (&ge;0.8 units/kg), mean duration of action is longer and less variable (22 to 23 hours).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_62_2028=[""].join("\n");
var outline_f1_62_2028=null;
var title_f1_62_2029="Adult thoracic effective doses";
var content_f1_62_2029=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F82239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F82239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Adult thoracic effective doses",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Procedure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Modality",
"       </td>",
"       <td class=\"subtitle1\">",
"        Average effective dose (mSv)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of chest x-rays (PA/lateral) with equivalent radiation dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest radiograph (posteroanterior)",
"       </td>",
"       <td>",
"        Conventional radiography",
"       </td>",
"       <td>",
"        0.02",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PA and lateral chest radiographs",
"       </td>",
"       <td>",
"        Conventional radiography",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroid scan (iodine 123)",
"       </td>",
"       <td>",
"        Nuclear medicine",
"       </td>",
"       <td>",
"        1.9",
"       </td>",
"       <td>",
"        19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lung ventilation-perfusion scan",
"       </td>",
"       <td>",
"        Nuclear medicine",
"       </td>",
"       <td>",
"        2.2",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thoracic angiogram",
"       </td>",
"       <td>",
"        Conventional fluoroscopy or interventional radiology",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parathyroid scan",
"       </td>",
"       <td>",
"        Nuclear medicine",
"       </td>",
"       <td>",
"        6.7",
"       </td>",
"       <td>",
"        67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Conventional coronary angiogram",
"       </td>",
"       <td>",
"        Conventional fluoroscopy or interventional radiology",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CT chest",
"       </td>",
"       <td>",
"        Computed tomography",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nuclear cardiac stress test",
"       </td>",
"       <td>",
"        Nuclear medicine",
"       </td>",
"       <td>",
"        9.4-12.8",
"       </td>",
"       <td>",
"        94-128",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac PET",
"       </td>",
"       <td>",
"        Nuclear medicine",
"       </td>",
"       <td>",
"        14.1",
"       </td>",
"       <td>",
"        141",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CT pulmonary embolism protocol",
"       </td>",
"       <td>",
"        Computed tomography",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        150",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coronary angioplasty or stent",
"       </td>",
"       <td>",
"        Conventional fluoroscopy or interventional radiology",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        150",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CT coronary angiogram",
"       </td>",
"       <td>",
"        Computed tomography",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        160",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PET: positron-emission tomography.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Mettler, FA, Huda, W, Yoshizumi, TT, Mahesh, M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology 2008; 248:254.",
"       </li>",
"       <li>",
"        Smith-Bindman, R, Lipson, J, Marcus, R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med 2009; 169:2078.",
"       </li>",
"       <li>",
"        Shrimpton, PC, Hillier, MC, Lewis, MA, Dunn, M. National survey of doses from CT in the UK: 2003. Br J Radiol 2006; 79:968.",
"       </li>",
"       <li>",
"        Diederich, S, Lenzen, H. Radiation exposure associated with imaging of the chest: comparison of different radiographic and computed tomography techniques. Cancer 2000; 89:2457.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_62_2029=[""].join("\n");
var outline_f1_62_2029=null;
var title_f1_62_2030="MIs prevented and harms of aspirin for 10 years";
var content_f1_62_2030=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated myocardial infarctions (MIs) prevented and estimated harms of using aspirin for 10 years in a hypothetical cohort of 1000 men",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Variable",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Estimated MIs prevented (per 1000 men),",
"        <em>",
"         n",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        10-year CHD risk, percent",
"       </td>",
"       <td class=\"subtitle2\">",
"        Age 45 to 59 years",
"       </td>",
"       <td class=\"subtitle2\">",
"        Age 60 to 69 years",
"       </td>",
"       <td class=\"subtitle2\">",
"        Age 70 to 79 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        <strong>",
"         3.2",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         3.2",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         3.2",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td>",
"        <strong>",
"         6.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         6.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         6.4",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td>",
"        <strong>",
"         9.6",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         9.6",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         9.6",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4",
"       </td>",
"       <td>",
"        12.8",
"       </td>",
"       <td>",
"        <strong>",
"         12.8",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         12.8",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        <strong>",
"         16",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         16",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6",
"       </td>",
"       <td>",
"        19.2",
"       </td>",
"       <td>",
"        <strong>",
"         19.2",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         19.2",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7",
"       </td>",
"       <td>",
"        22.4",
"       </td>",
"       <td>",
"        <strong>",
"         22.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         22.4",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        8",
"       </td>",
"       <td>",
"        25.6",
"       </td>",
"       <td>",
"        <strong>",
"         25.6",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         25.6",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9",
"       </td>",
"       <td>",
"        28.8",
"       </td>",
"       <td>",
"        28.8",
"       </td>",
"       <td>",
"        <strong>",
"         28.8",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        <strong>",
"         32",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        11",
"       </td>",
"       <td>",
"        35.2",
"       </td>",
"       <td>",
"        35.2",
"       </td>",
"       <td>",
"        <strong>",
"         35.2",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        12",
"       </td>",
"       <td>",
"        38.4",
"       </td>",
"       <td>",
"        38.4",
"       </td>",
"       <td>",
"        38.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        13",
"       </td>",
"       <td>",
"        41.6",
"       </td>",
"       <td>",
"        41.6",
"       </td>",
"       <td>",
"        41.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        14",
"       </td>",
"       <td>",
"        44.8",
"       </td>",
"       <td>",
"        44.8",
"       </td>",
"       <td>",
"        44.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        15",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        48",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        16",
"       </td>",
"       <td>",
"        51.2",
"       </td>",
"       <td>",
"        51.2",
"       </td>",
"       <td>",
"        51.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        17",
"       </td>",
"       <td>",
"        54.4",
"       </td>",
"       <td>",
"        54.4",
"       </td>",
"       <td>",
"        54.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        18",
"       </td>",
"       <td>",
"        57.6",
"       </td>",
"       <td>",
"        57.6",
"       </td>",
"       <td>",
"        57.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        19",
"       </td>",
"       <td>",
"        60.8",
"       </td>",
"       <td>",
"        60.8",
"       </td>",
"       <td>",
"        60.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        20",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        64",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Type of event",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"3\">",
"        Estimated harms,",
"        <em>",
"         n",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        GI bleeding",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemorrhagic stroke",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    As indicated, the estimated number of MIs prevented varies with 10-year CHD risk. The estimated harms of using aspirin vary with age. Therefore, both 10-year CHD risk and age must be considered when determining whether the potential harms of aspirin use outweigh the potential benefit in terms of MIs prevented. The boldfaced numbers indicate the combinations of 10-year CHD risk and age for which the number of harms (GI bleeding and hemorrhagic stroke) are greater than or approximately equal to the number of MIs prevented.*",
"    <div class=\"footnotes\">",
"     CHD: coronary heart disease; GI: gastrointestinal; MI: myocardial infarction.",
"     <br>",
"      * Calculations of estimated benefits and harms rely on assumptions and are by nature somewhat imprecise. Estimates of benefits and harms, especially at the borders of the boldfaced and non-boldfaced areas, should be considered in the full context of clinical decision making and used to stimulate shared decision making. The calculations in the table are based on the following assumptions: that there is a 32 percent risk reduction of MIs with regular aspirin use and that gastrointestinal bleeding includes serious hemorrhage, perforation, or other complications leading to hospitalization or death. The harm of GI bleeding in the table assumes that the risk for GI bleeding increases with age and that the men are not taking nonsteroidal anti-inflammatory drugs, do not have upper GI pain, or do not have a history of GI ulcer. Estimates are based on age and 10-year CHD risk.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: US Preventive Services Task Force. Aspirin for the Prevention of Cardiovascular Disease: Recommendation Statement. AHRQ Publication No. 09-05129-EF-2, March 2009. Agency for Healthcare Research and Quality, Rockville, MD. file://www.ahrq.gov/clinic/uspstf09/aspirincvd/aspcvdrs.htm.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_62_2030=[""].join("\n");
var outline_f1_62_2030=null;
var title_f1_62_2031="Balloon dilation PD stricture";
var content_f1_62_2031=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Balloon dilation of pancreatic duct stricture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 256px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This image shows a balloon that has been inflated within a stricture in the main pancreatic duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marc Catalano, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_62_2031=[""].join("\n");
var outline_f1_62_2031=null;
